Element Biosciences News

Element Biosciences Launches Trinity™ – A Revolutionary Targeted Sequencing Innovation to Streamline Genomic Research

2024-10-16T04:00:00-07:00

Element Biosciences has partnered with Integrated DNA Technologies (IDT) and Twist Bioscience to provide the necessary exome-targeting tools for the Trinity workflow

SAN DIEGO, CA (October 16, 2024) – Element Biosciences, Inc., a developer of pioneering technologies to empower science, today introduced Trinity™ - an innovative solution that simplifies target capture sequencing by eliminating or moving traditionally time-consuming steps to the AVITI™ System and providing customers with the option to dramatically reduce hybridization time, without sacrificing cost or quality.

Launching today at BEYOND, Element’s inaugural annual virtual event, the first Trinity product is an exome target capture solution that allows researchers to concentrate sequencing on the most relevant genomic regions, reducing both time and costs compared to whole genome sequencing (WGS). By simplifying the operational complexity of exome sequencing, Trinity makes advanced genomic research faster and more accessible than ever, initially for exomes but rapidly expanding to support custom panels of any size across a wide array of applications, including comprehensive cancer panels, respiratory panels, and MRD.

Trinity is the first major advancement in exome target capture sequencing in over two decades, streamlining a traditionally complex, hands-on process to capture and sequence key regions of DNA. Trinity uses a new flow cell and paired reagents to complete the capture, wash, and sequencing steps on the AVITI™ System, eliminating the need for specialized equipment and saving up to five hours of manual work. With the addition of a 1-hour fast hybridization option, Trinity enables same-day sequencing results, making it ideal for time-sensitive studies.

"Trinity will make hybrid selection sequencing no more complex than generating a sequencing library and starting a sequencer." said Shawn Levy, Chief Scientific Officer and SVP of Applications. “It radically changes a long-standing workflow in targeted sequencing."

Trinity™ is available for order beginning today, October 16, 2024, and integrates seamlessly with Element’s AVITI™ and AVITI24™ systems. Element Biosciences has partnered with Integrated DNA Technologies (IDT) and Twist Bioscience to provide the necessary exome-targeting tools for the Trinity workflow.

"Trinity saves researchers valuable time and lets them concentrate on the most critical aspects of their work," said Molly He, CEO and co-founder of Element Biosciences. "With Trinity, we continue to push the boundaries of innovation, providing a comprehensive suite of genomic tools in a unified platform."

"This partnership with Element Biosciences exemplifies IDT's high-performing chemistry and exome design, and commitment to empowering researchers by delivering cutting-edge tools that enhance efficiency,” says Linda De Jesus, Vice President and General Manager, Global Commercial Operations at IDT. “By integrating IDT's exome-targeting technologies into the Trinity workflow, we are enabling our customers to achieve more actionable genomic insights, accelerating their research timelines and advancing scientific discovery."

"In our continued commitment to advance sequencing solutions across platforms, Twist is pleased to continue our collaboration with Element and the release of Trinity-compatible workflows," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. "Incorporating the evolution of our Fast Hyb workflows to reduce the time from sample to sequencer significantly enables applications which demand rapid turnaround without compromising data quality, pushing the boundaries of sequencing innovation and opening doors to new possibilities."

About Element Biosciences, Inc.
Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact

Liz Robinson of CG Life
Element Biosciences
+1 312-997-2436
lrobinson@cglife.com

Investor Contact

IR@elembio.com

Element Biosciences Raises Over $277 Million to Develop and Commercialize Differentiated Products and Continue Rapid Growth

2024-07-11T04:00:00-07:00

SAN DIEGO, CA (July 10, 2024) – Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced over $277 million in Series D investment to support its growing global customer base with disruptive DNA sequencing and multi-omics technologies for years to come. The oversubscribed round was led by Wellington Management with participation from new and existing investors, including Samsung Electronics, Fidelity, Foresite Capital, funds and accounts advised by T. Rowe Price Associates, Inc, and Venrock, among others. This brings Element’s cumulative raise to over $680 million.

“After years of watching Element’s impressive progress from the sidelines, we are excited to support the company’s next chapter of growth and development,” said Joshua Sommerfeld, healthcare sector lead at Wellington Management Private Investing. “Their platform combines quality, cost, and flexibility advantages that disrupt the incumbent price curve. By bringing end-to-end integrated multi-omic workflows onto a single system, Element has potential to accelerate biological discovery.”

“Molly and the team at Element are cementing their position in a highly competitive environment,” said Mr. Jong-Hee (JH) Han, Vice Chairman and CEO at Samsung Electronics. “Their products set a new industry standard and are foundational to the next wave of biological innovation that will help researchers and businesses around the globe deliver on the promises of precision medicine and artificial intelligence. We are incredibly excited about Element’s vision to make precision medicine affordable and are impressed with the team they built together.”

This funding will further support the commercialization of AVITI™, Element’s benchtop DNA sequencer, and bolster the upcoming launch of AVITI24™, the first instrument to combine state-of-the-art sequencing and cyto-profiling (mapping cell characteristics) into a single integrated biology platform. AVITI24 revolutionizes research by enabling simultaneous examination of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells – empowering researchers to gain unparalleled insights into biological systems with unprecedented ease.

“After a decade of an 800-pound gorilla dominating the ecosystem, it has been a privilege to help the exceptional Element team deliver customer-centric products that advance the quality, affordability and democratization of genomic analysis,” said Bryan Roberts, Partner at Venrock and an early investor in Element, alongside Jim Tananbaum at Foresite Capital.

“We cofounded Element based on a simple belief that cutting-edge science should be available to the entire research community. Element has taken the first step to democratize sequencing and will continue helping the community uncover the secrets of biology with high-quality, flexible, rapidly iterative, and affordable tools that are accessible to more scientists.” said Molly He Ph.D., CEO, Element Biosciences. “Element has grown an increasingly large, enthusiastic, and loyal customer base thanks to our innovative products and a collaborative, tenacious team that has remained committed to Element’s mission. An oversubscribed round against the backdrop of a challenging macroeconomic environment is a testament to our mission. With the support of our new and existing investors, Element is solidifying its future as the next name-brand biological tools company – a true unicorn.”

In the last 12 months, Element’s install base of AVITI has grown from approximately 40 units to more than 190. Element’s customers span a diverse set of industries including academia, biotech, cancer research, and agricultural science in more than 25 countries, and its technologies are used by pioneering organizations like Cerba Research, Cornell University, Garvan Institute, Revvity, Stowers Institute, VIB, and others.

The University of Minnesota Genomics Center (UMGC), which installed its first AVITI in mid 2023, has purchased four additional AVITIs over the past year. Dr. Kenny Beckman, Director of the UMGC, has been pleased with its performance. “The AVITI is simple to operate, easy to integrate from a data perspective, and the quality of the output is higher than with our legacy NGS instruments,” said Dr. Beckman. “The AVITI’s scale is a great fit for our clients, most of whom need both fast turnaround and low cost.”

“Precision medicine's vast potential is being unlocked by cutting-edge genomic and multiomic technologies. Element's groundbreaking sequencing is driving significant advancements in precision diagnostics research across critical disease areas,” said Thomas P. Slavin, Chief Scientific Officer at HALO Precision Diagnostics, which installed four AVITI sequencers over alternative high-throughput offerings from an NGS competitor in 2023.

Reflecting on Element’s journey, Molly added, “We simply wouldn’t have made it to this remarkable stage without the initial pioneers and risk-takers who formed our earliest customer base. Element is especially grateful for their support.”

About Element Biosciences, Inc.
Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact
media@elembio.com

Element Biosciences Fortifies its Executive Team with Experts in Artificial Intelligence and Product Development

2024-06-26T04:00:00-07:00

SAN DIEGO, CA (June 26, 2024) – Element Biosciences, Inc., a developer of pioneering technologies to empower science, today announced the additions of two industry-leading artificial intelligence and portfolio management experts to its executive team. The appointments will build Element’s leadership as it expands with innovative products and capabilities.

Element is pleased to announce the appointment of Amirali Kia, PhD, as Vice President of Artificial Intelligence. Dr. Kia will apply his extensive expertise in Artificial Intelligence within the Life Sciences sector to enhance the value of Element's current and future products. His role will include optimizing the utility of the comprehensive multiomic datasets generated by AVITI24™.

Element is also appointing Tina Tian, PhD, as Vice President of Portfolio Management. Since launching AVITI™ in 2022, Element has continually released new kits and chemistries, driving innovation and strong differentiation for its products. Dr. Tian will continue Element’s relentless drive, taking charge of program and portfolio management.

“The key to Element’s success and market growth is our passionate and high-performing team who pushes the boundary of innovations. The expertise Amirali and Tina bring to Element will expedite our work to provide innovative products for the future of biology.” said Molly He, CEO, Element Biosciences. “We will continue to redefine what is possible on a sequencer and help labs around the globe shift their science into a higher gear.”

About Amirali Kia, PhD, Vice President of Artificial Intelligence

Amirali brings over 12 years of expertise in applying machine learning and data science to biology and biotechnology. He has published numerous articles in the fields of machine learning and computational biology.

Before joining Element Biosciences, he served as the Vice President of AI and Data Science at Deepcell, where he helped expand the company's AI research initiatives in cell morphology. Prior to this, he was the Vice President of AI and Computational Biology at Harbinger Health, where he played a pivotal role in establishing the AI infrastructure and developing algorithms for early cancer detection in blood samples.

Amirali began his industrial career at Illumina following the completion of his PhD. As the Director of the Core-AI team, he successfully harnessed AI for various core technologies at Illumina, ranging from instrument analysis algorithms to protein engineering. His extensive industrial experience encompasses tools and instruments, large molecule discovery, and diagnostics.

Amirali holds a PhD from Stanford University in High Performance Computing, with a focus on its applications in biology.

About Tina Tian, PhD, Vice President of Portfolio Management

Tina brings over 25 years of management experience in the biotech industry across the areas of portfolio management, program management, R&D and CLIA laboratory management.

Prior to joining Element, Tina was the Head of Pharma Services at Roche Diagnostics, leading a cross-functional CLIA team to provide cutting-edge clinical services to pharma customers. Before joining Roche, Tina was a Senior Director of Portfolio and Program Management at Thermo Fisher Scientific’s Clinical Sequencing Division, where she played a pivotal role in building product roadmaps, establishing a PMO team as well as delivering products to customers. Tina’s experience also includes senior PMO roles at Pacific Biosciences and Affymetrix.

Tina holds a PhD in Biochemistry from the Johns Hopkins Medical School and received her postdoctoral training from the National Institutes of Health.

About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multiomics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact:

Melissa Musiker
Element Biosciences
Melissa.Musiker@elembio.com

Element Biosciences to Showcase Sequencing Innovations at the European Human Genetics Conference

2024-05-30T04:00:00-07:00

Customers laud the positive impact of AVITI on advancing their scientific research

SAN DIEGO, CA (May 30, 2024) – Element Biosciences, Inc., developer of pioneering technologies to empower science, will showcase the rapidly growing use of its AVITI™ System sequencer across the European scientific community at the European Human Genetics Conference 2024 in Berlin, Germany, on June 1.

During ESHG 2024, which runs from June 1-4, Element Biosciences’ Chief Technology Officer and Co-Founder Michael Previte will share the latest details on the AVITI24™, the first platform to combine state-of-the-art sequencing and multiomic cell analysis in one integrated biology tool. The AVITI24 enables the simultaneous measurement of multiple analytes, including DNA, RNA, proteins, phosphorylated proteins, and morphology, in up to one million cells per flow cell.

“At ESHG, we’re excited to show the transformative power of AVITI and highlight how we’re advancing our mission to increase access to high-quality, affordable tools for complex biological research through AVITI24,” said Previte.

The AVITI System is expanding access to faster, more efficient and innovative sequencing for European scientific labs, with Element’s technologies now being used by researchers in most countries in Europe. With its AVITI24 open for preorders, Element also announced that existing customers are prebooking ahead of shipment, including the National Genomics Infrastructure (NGI) at SciLifeLab, a world-leading Swedish national center for large-scale research and one of the largest molecular biology research infrastructures in Europe.

"As part of the National Genomics Infrastructure, we're committed to staying at the forefront of technology,” said Robert Månsson Welinder, Head of Strategic Relations at NGI. “Element's AVITI24 will help us push this frontier and allow our scientific community to pursue new and exciting science."

Leading European scientists emphasized the positive impact the AVITI has had on advancing their scientific research. Igor Fijalkowski, researcher at the Center for Medical Genetics at Ghent University in Belgium, noted the ease of adoption and flexibility of the platform saying “Over the last year or so we performed more than 100 runs of AVITI sequencing and overall, across multiple applications, the sequencing quality has been excellent. The transition was frictionless, so we are very happy with the way the sequencer has been performing.”

Several other researchers noted the cost-effectiveness, high quality, and flexibility of the AVITI platform. “Since the installation of our AVITI we have been blown away by its flexibility and quality outputs,” said Megan Hamilton, Genomics Facility Manager at the Babraham Institute in Cambridge, United Kingdom. Petri Auvinen, Research Director at the Institute of Biotechnology, University of Helsinki, Finland, said “AVITI seems to be the most efficient and most legitimate system to run a new chemistry for sequencing.”

Others called out the unique features of the AVITI not available on other platforms. “The cost-effectiveness of AVITI adds to its high sequencing quality of Q40-50, which makes it an important device in the future of cancer research,” said Romain Boidot, molecular biologist at the Georges-François Leclerc Center, France. Also in France, Charles Poncet, lab manager at INRAE, said “We chose AVITI for its combination of performance, price of the instrument and reagents, flexibility, and applications. We also had the chance to test AVITI with our wheat samples and the results were excellent, especially for an organism with such complex genetics.”

Two years after launching AVITI, the sequencer that provides the highest quality sequencing on a benchtop, Element has continued to innovate on its modular platform. It has introduced faster run times, expanded kit offerings, the Elembio Cloud software platform, and industry-leading affordability, while maintaining unprecedented accuracy.

About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn,X (Twitter), and Facebook.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Announces Record Sequencer Installation Growth Ahead of Participation in Investor Conferences

2024-05-14T04:00:00-07:00

SAN DIEGO, May 14, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced record growth in installations of its AVITI™ System ahead of its participation in upcoming investor conferences.

Element has now received more than 200 cumulative orders of AVITI – the sequencer that provides the highest quality sequencing on a benchtop for as low as $200 per genome. In just one year, the company’s installed base has grown from more than 20 units to more than 150. Element’s sequencers now empower research across academia, biotech, cancer research, and agricultural science in more than 25 countries.

Senior executives, including Molly He, CEO and Co-founder, and Logan Zinser, SVP of Finance, will share the news of the company's continued growth at the following upcoming investor conferences:

Bank of America Merrill Lynch Global Healthcare Conference 2024 (Las Vegas – May 14–16)
Jefferies Global Healthcare Conference (New York – June 5–6)
Goldman Sachs 45^th Annual Global Healthcare Conference (Miami – June 10–13)
Morgan Stanley 22^nd Annual Global Healthcare Conference (New York – September 4–6)
UBS Global Healthcare Conference (Rancho Palos Verdes, CA – November 11–14)
Stifel Healthcare Conference 2024 (New York – November 18–19)

“Our founding vision was to increase access to high-quality, affordable tools to help people own their own biology research, regardless of how well they are funded,” said Element CEO Molly He. “AVITI as our first product is now being used across the world to expand scientific possibilities, driving unprecedented growth for Element. Now we aim to expand this mission beyond sequencing to maximize scientific information and support the next wave of discovery to ultimately understand the underlying biology of all species.”

Later this year, Element will introduce groundbreaking new technology to the field through AVITI24™– an innovative, dual-function platform integrating state-of-the-art sequencing and multiomic cell analysis. Also launching this year is Trinity™, Element’s on-board enrichment solution that could revolutionize targeted sequencing for clinical research by radically simplifying the workflow.

“Our technologies aren't merely driving business expansion,” Molly He added, “they're empowering researchers to tackle complex biological problems and make transformative discoveries.”

About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element CEO Molly He Named to Inc. Business Media Female Founders List

2024-04-09T04:00:00-07:00

SAN DIEGO, CA, April 9, 2024 – Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced that Inc. Business Media has named Element CEO and Co-founder Molly He to its 2024 Female Founders list. The annual list honors a bold group of 250 women whose ideas and innovations are shaping the world and rewriting the rules of business.

Molly was specifically chosen by Inc. for her leadership and fundraising, driving Element’s mission to open the world of biology to new possibilities. Her accomplishments include leading the company through five successful rounds of fundraising, achieving one of the fastest growth rates among companies in the field, and surpassing $25 million in revenue in 2023.

“I’m honored to be named one of Inc’s top 250 female founders – an initiative that sends a powerful message that women and girls have limitless potential,” she said. “I helped found Element with a singular aim: to make a significant impact. Our mission is fueled by the determination to ensure that cutting-edge technology is accessible to everyone. This recognition is a reflection of my team, whose unwavering commitment to opening up new scientific possibilities inspires me every day.”

"The past year, for many, will go down as one of the hardest ever—between a funding freeze and ad-spending pullback," said Diana Ransom, Inc. Executive Editor. "The female founders on this year's list are a testament to what triumph over adversity looks like.”

About Inc Female Founders List

Each year, Inc. editors review thousands of applications highlighting female founders who are challenging the status quo and tackling some of the world’s biggest problems. The list features women who have overcome challenges and lifted those around them while leading impactful organizations across the country.

About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Announces Availability of AVITI24, the First Benchtop Sequencer Capable of Direct Cell Profiling

2024-04-05T07:00:00-07:00

Element’s new multi-omics platform will be shipped by end of the year
AVITI24 offers an unprecedented view of cells at the molecular and functional level

SAN DIEGO, April 5, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, has begun taking orders for AVITI24™ the first instrument to combine state-of-the-art sequencing and cyto-profiling (mapping cell characteristics) into a single integrated biology platform, the company announced at the Annual Meeting of the American Association for Cancer Research.

AVITI24 revolutionizes research by enabling simultaneous examination of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells. Powered by Element’s new Teton™ chemistry, AVITI24 expands on AVITI’s best-in-class sequencing capabilities to offer new multi-omics functionality, simplifying results in one multi-omic read-out in less than 24 hours. This technology is particularly relevant for cancer researchers, facilitating in-depth exploration of the links between the molecular makeup of cancer cells and how they function within complex tumors. With the ability to profile up to one million cells in a single experiment, AVITI24 can maximize detection of rare cells such as residual cancer cells or tumor-specific immune cells, which are difficult to detect using conventional methods.

The AVITI24 is now available for pre-order at a U.S. list price of $424,000 or as an upgrade to the AVITI System at a list price of $150,000. Before June 30, 2024, customers can save $50,000 by pre-ordering AVITI24 as part of their AVITI purchase. Teton panels, used for cyto-profiling on the AVITI24, are designed to maximize value and ensure cost-effectiveness per cell or sample, providing a meaningful cost advantage compared to other approaches and empowering researchers to drive transformative discoveries without constraints. For more information, please visit: https://www.elementbiosciences.com/preorder-aviti24 and look for Element at AACR, Booth 605.

AVITI24 will launch with four fixed Teton panels, including two focused on deep profiling of the MAPK signaling pathway, which plays a crucial role in the development and progression of tumors. These MAPK panels aid in cancer biology exploration and studying therapeutic response and resistance. Additionally, two other fixed panels will enable human immune profiling and neuroscience applications. The former allows researchers to understand the dynamic interplay between immune cells and disease states, while the latter captures diverse cell types and functional states within neuronal circuits. With the ability to culture cells in a 12-well format, Teton further enables drug development by allowing iterative testing of novel therapies, doses, and combinations.

An expanding roadmap of fixed and custom Teton panels will enable broad applications across oncology, immunology, neuroscience and more.

“Today, we are redefining what a sequencer can do by streamlining multiple conventional stages of discovery into a single powerful platform,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “The MAPK pathway panel is only the beginning. We are planning more targeted panels to address different biological problems, and we welcome input from the scientific community about what we develop next. To beat cancer and other genetic diseases, we have to do this together, and that starts with cutting-edge innovation to bring researchers the tools they need to accelerate discovery.”

About Element Biosciences, Inc.

Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn,X (Twitter), and Facebook.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Announces Senior Vice President of Global Sales and Support

2024-03-12T04:00:00-07:00

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support.

In her new role, Danae will spearhead Element's commercial sales initiatives, overseeing regions including North America, Asia Pacific, EMEA, Latin America and others worldwide. As Element expands its global customer base, she will work with Element customers and distributors internationally to maximize operational excellence and translate feedback into product innovations.

“Danae will play an instrumental role in expanding our global presence and strengthening relationships with our customers and distributors across the world,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “Danae’s expertise and proven track record of success will help Element advance our mission to empower scientists with the most innovative tools to catalyze discovery.”

Danae was most recently 10x Genomics’ Vice President and General Manager for the Americas region after previously leading its global sales programs, global distribution, and strategic partnerships. Before joining 10x Genomics, she held global sales management roles at Illumina and was Distribution Territory Manager for Beckman Coulter.

“I’m excited to drive the commercialization of Element’s current AVITI success and planned innovation capabilities to labs across the world,” said Danae Van Oene. “I have seen firsthand how the industry is rapidly evolving to meet the needs of scientists, and I look forward to helping enable the future of biology.”

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing and other omics technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Named to “Fierce 15” List of Medtech Innovators

2024-03-04T07:00:00-08:00

SAN DIEGO, CA, March 4, 2024 – Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medical technology companies. The annual special report features the most innovative private medtech companies in the industry.

“This award is a testament to the hard work and determination of the entire Element team,” said Element CEO and Co-founder Molly He. “In an industry long dominated by legacy players, we have consistently broken down barriers through innovation, empowering scientists to accelerate their progress.”

Element was chosen for the remarkable strides they are making to democratize sequencing and biological tools globally, bringing more cost-effective, accessible tools to labs across the world. This year, Element is setting its sights beyond DNA, and in January the company shared a roadmap for new products launching in 2024, including AVITI24, the first instrument that can simultaneously analyze multiple biological signals (DNA, RNA, proteins, phosphorylated proteins, and cell morphology).

“Every year we celebrate a few of the most innovative toolmakers, whether they’re focused on helping clinicians reach, diagnose and treat the sick, or assisting the researchers chasing the next scientific and medical breakthroughs,” said Conor Hale, senior editor of Fierce Medtech. “These companies exemplify the ability of the medtech industry to turn cutting-edge ideas into meaningful outcomes and make them accessible on a large scale.”

About Fierce Medtech

Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. Top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing and other omics technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn and Facebook.

Media Contact

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Molly He Honored as a CNBC Changemaker in Inaugural List of Women Transforming Business

2024-02-28T03:00:00-08:00

SAN DIEGO, Feb. 28, 2024 /PRNewswire/ – Element Biosciences, Inc., developer of pioneering technologies to empower science, announced that Element CEO and Co-founder Molly He, PhD, was named to the inaugural CNBC Changemakers list of trailblazing female leaders.

As a first-generation Asian female leader, Molly was honored by CNBC for spearheading a remarkable undertaking to democratize sequencing and biological tools globally. Her team has grown to over 300 people and has sold over 160 instrument placements across 20 countries, opening access to emerging markets like India and Vietnam. From the founding of the company in late 2017, Molly’s leadership has helped her team navigate the COVID pandemic, market downturns, and a highly competitive sequencing market with a dominant incumbent. Her work is a reflection of her commitment to collaborative science through fairness and accessibility for the research community.

“Today is a great honor and a true testament to the journey the Element team has embarked on together since the company’s founding,” Molly He said. “It was a daunting decision to chart a new path as a CEO and co-founder, especially when starting a company in a 1200-square-foot basement with no air conditioning and an idea that only existed on paper. But through grit and persistence, we have shattered stereotypes and created a company that is going against the odds to make a positive impact in the world.”

“We are incredibly proud to see Molly recognized on CNBC's inaugural Changemakers list,” said Bryan Roberts, PhD, partner at Venrock and member of the Element Biosciences Board of Directors. “Molly's visionary leadership has been instrumental in driving Element's mission to empower science through pioneering technologies. This is a well-deserved acknowledgment of her success in revolutionizing the field. We continue to support Element's innovative journey and look forward to witnessing further advancements that will shape the future of biosciences."

Molly He, Michael Previte, and Matthew Kellinger founded Element in 2017 to disrupt and democratize life sciences research and development through innovative tools for sequencing and beyond. In 2022, Element launched the AVITI System to make high quality affordable sequencing available to labs of all sizes. Less than a year after launch, Element was the first to make whole genome sequencing available for $200 per genome. In 2024, the company announced new multi-omics capabilities, introduced the highest-quality commercial sequencing kit to the market, and made workflow improvements that allow researchers to spend more time reviewing results and less time preparing samples.

“Molly has exemplified a steadfast commitment to hard work, authenticity and harmony,” said Michael Previte, PhD, Element CTO, SVP of R&D, and Co-founder. “She practices and leads with a team-first commitment that has allowed all of us to overcome significant challenges and obstacles in a highly competitive landscape. These commitments have created a company culture that strives to overdeliver on promises and continue to provide the best value for the customers.”

About Element Biosciences, Inc.

Element Biosciences Media Contact:

Kristi Heim
kristi.heim@elembio.com

Volta Labs and Element Biosciences Announce Collaboration to Enable Walk-Away Sample Prep and Sequencing on the AVITI™ System

2024-02-07T04:00:00-08:00

BOSTON and SAN DIEGO (Feb. 7, 2024) -- Volta Labs, a genomics applications company, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to optimize sequencing throughput with the launch of Volta's Callisto™ Sample Prep System for Element's AVITI™.

The combination of Volta Labs' Callisto and availability of VoltaPrep™ kits to prepare libraries for the AVITI System provides an efficient and low-cost end-to-end sequencing solution for customers, removing bottlenecks and accelerating the time to results.

"The work done by Element to broaden access to affordable, high-quality sequencing is unprecedented," said Udayan Umapathi, CEO at Volta Labs. "With this partnership, we will join forces with the Element team to offer an end-to-end solution to break the sample prep bottleneck and support sequencing at scale."

"When we launched AVITI, it brought unmatched performance and affordability in benchtop sequencing. In commercial partnership with Volta Labs, we are taking another critical step to improve ease and accessibility to customers," said Yaron Hakak, PhD, SVP of Corporate and Business Development at Element Biosciences. "Labs will now have exceptional flexibility in the sequencing process from sample prep through analysis."

This collaboration expands the reach of Volta's novel sample prep system, providing labs the flexibility to sequence smaller batches of reactions more frequently and at a lower cost. The Callisto Sample Prep System supports up to 24 reactions per run across at least eight applications, prepped for sequencing in hours. Combined with AVITI's guided workflows and flexible system settings, customizing an experiment to produce accurate, specialized results has never been more efficient or reliable.

About Volta Labs

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to improve the performance, scalability, and consistency of sample preparation for genomic analyses. Volta Labs is transforming the way new biological protocols are developed, implemented, and executed, allowing scientists to focus on what they do best -- pushing the boundaries of biology.

Media Contact:

Kim Miller
Volta Labs
kmiller@voltalabs.co

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing and other omics technology for research markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic research. To learn more about Element, please visit www.elementbiosciences.com.

Media Contact:

Kristi Heim
Element Biosciences
kristi.heim@elembio.com

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

2024-02-06T05:00:00-08:00

Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Calif. – February 6, 2024 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

“Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally. Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Because our tools are sequencer agnostic, we can extend the reach of our products with innovative companies like Element, and continue our commitment to empowering researchers to accelerate breakthroughs in scientific discovery by providing advanced tools.”

“We’ve laid out an ambitious product roadmap for 2024 to redefine what is possible on a sequencer and make it even easier for labs to produce the highest quality data at a low cost,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “With the Twist for Element Exome Workflow, we are able to provide our customers with easy access to Twist’s Exome 2.0 panel and high performing library preparation and target enrichment reagents, saving them potential downstream sequencing costs by reducing per sample sequencing requirements.”

The Twist for Element Exome Workflow is a purpose-built solution for Element’s AVITI chemistry, alleviating the need for additional workflow steps for linear library conversion. The workflow will include Twist’s library preparation and target enrichment bundled with the Exome 2.0 and comprehensive spike-in. The Exome 2.0 delivers best-in-class sequencing due to its high uniformity and low off-target rate. It is designed to detect rare and inherited diseases, as well as germline cancers.

If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here.

About Element Biosciences, Inc.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow to save researchers potential downstream sequencing costs by reducing per sample sequencing requirements. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

For Element Biosciences:

Kristi Heim
kristi.heim@elembio.com

For Twist Bioscience:

For Investors:

Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:

Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Element Biosciences and DNAnexus® Announce Collaboration to Advance Multi-Omics Analysis

2024-02-06T04:00:00-08:00

Direct integration allows customers to stream data from Element’s AVITI™ System directly to DNAnexus

SAN DIEGO, CA (Feb. 6, 2024) – Element Biosciences, Inc., developer of pioneering technologies to empower science, announced a collaboration with DNAnexus, provider of the Precision Health Data Cloud, to allow customers to stream data from Element’s AVITI™ System directly to their DNAnexus account. The collaboration combines the unmatched performance of AVITI sequencing with the secure and full-featured multi-omic analysis platform of DNAnexus. The integration of AVITI with DNAnexus will be available to customers in Q1 2024.

"We are thrilled to have DNAnexus as a partner in the growing Element Biosciences analysis ecosystem," said Francisco Garcia, PhD, SVP of Informatics at Element Biosciences, speaking at the Advances in Genome Biology and Technology (AGBT) 2024 conference. "This collaboration provides our customers with direct integration to DNAnexus' robust, flexible and user-friendly multi-modal analysis platform.”

“We’re excited to partner with Element Biosciences to provide a seamless experience for customers to generate, analyze and interpret genomic data on DNAnexus,” said Thomas Laur, CEO at DNAnexus. “Element Biosciences has established itself as a leading sequencing technology innovator and we are proud to join forces to help streamline multi-omics research.”

Key advantages of the combined features include:

Streamlined Data Transfer: AVITI instruments, configured through ElemBio Cloud, can effortlessly stream data directly to a customer's DNAnexus account.

Bases2Fastq Availability: Element's Bases2Fastq global application for demultiplexing and FASTQ generation is now published as an application on DNAnexus, accessible to all users.

Automated Workflows: Users have the flexibility to automatically launch Bases2Fastq and additional secondary/tertiary analyses available on DNAnexus as soon as the data are fully uploaded, providing rapid insights post-run completion.

The collaboration embodies Element's commitment to empowering customers with choice and flexibility and sets the stage for advancing multi-omics research and applications.

About Element Biosciences, Inc.

About DNAnexus

DNAnexus enables biomedical organizations to accelerate scientific discovery and improve patient care with the Precision Health Data Cloud. The company provides scientific innovators and healthcare professionals with the ability to manage, analyze, and collaborate on multi-omic, clinical and real-world data to unlock insights. DNAnexus actively manages more than 100 petabytes of data on behalf of a growing network of collaborations with leading pharmaceutical, clinical diagnostic, academic research, biobank, and government organizations. Today, more than 45,000 users across 48 countries and over 130 enterprise customers are harnessing the full potential of their data with the scalable and secure Precision Health Data Cloud. DNAnexus is headquartered in Mountain View, Calif. For more information, visit www.dnanexus.com or follow @DNAnexus.

Integrated DNA Technologies and Element Biosciences Accelerate Next Generation Sequencing Workflows for Element’s AVITI™ System

2024-02-05T06:00:00-08:00

Companies unite in shared vision of enabling researchers to translate genomic insights to groundbreaking discoveries
Partnership includes launch of new IDT xGen™ NGS products designed exclusively for Element’s AVITI System
Equips AVITI users with differentiated NGS tools to support a wide range of NGS applications

CORALVILLE, Iowa and SAN DIEGO, Calif. (Feb. 5, 2024)—Life sciences companies Integrated DNA Technologies (IDT) and Element Biosciences, Inc. have bolstered their partnership with products to enable more efficient and streamlined next generation sequencing (NGS) workflows for users of the AVITI System, an innovative sequencing and multi-omics platform based on Element’s novel avidite base chemistry.

Launching today is a suite of high-quality adapters, universal blockers and library amplification primer mixes designed exclusively for the AVITI System. These products can support a wide range of applications, including DNA, RNA, and methylation sequencing workflows, as well as IDT’s proven hybridization capture chemistry. They also are intended to minimize sequence errors from PCR or sequencing that might impact demultiplexing. To learn more or place an order, visit www.idtdna.com/xGenElement.

“Researchers continue to be driven by solutions that empower them to translate their discoveries to actionable insights, and IDT remains steadfast in evolving its NGS portfolio to deliver on these needs,” said Linda De Jesus, VP/GM, Global Head of Commercial at IDT. “Our work with Element Biosciences reflects this commitment and today’s launch equips customers with tools designed specifically to enable key NGS applications on the AVITI System.”

“We are excited to work with IDT, a primary source for quality NGS components and solutions for manufacturers and end users around the world,” said Yaron Hakak, PhD, Senior Vice President of Corporate and Business Development at Element Biosciences. “Partnering with IDT will enable us to quickly scale native library prep on AVITI to serve its rapidly growing base of users.”

To support Element's AVITI System with native library construction and hybridization capture enrichment, IDT is offering the following stocked AVITI products:

xGen Stubby Adapter-UDI Primers for Element—stubby adapter and unique dual-index primer pairs for TA-ligation library preparation workflows where indexing by PCR is preferred. Available as single-use plates containing either 16 or 96 indexes, and a separate tube of stubby adapters with a matching number of reactions.
xGen Universal Blocking Oligos for Element—proprietary blockers designed specifically for Element Biosciences libraries for use in the hybridization capture workflow to reduce non-specific adapter interaction during probe hybridization and increase on-target capture performance. Available in 16 or 96 reaction sizes.
xGen Library Amplification Primer Mix for Element—premixed PCR primers, available in 16 or 96 reaction sizes, to increase yield for sequencing libraries post-hybridization capture.

About IDT

For more than 35 years, Integrated DNA Technologies, Inc. (IDT) has empowered genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, featuring the most advanced synthesis, modification, purification, and quality control capabilities available. Since its founding in 1987, IDT has progressed from a leading oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use.

IDT Media Contact:

Kristina Sarenas
800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA)
idtpr@idtdna.com

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing and other omics technology for research markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic research. To learn more about Element, please visit www.elementbiosciences.com.

Element Biosciences Media Contact:

Kristi Heim
kristi.heim@elembio.com

Element to Present Data on New Products and Multi-Omics Capabilities at AGBT

2024-02-05T04:00:00-08:00

Element will share results from the industry’s first commercial Q50 sequencing kit
Element’s customers report how innovative methods available on the AVITI out-perform legacy devices

SAN DIEGO, CA (February 5, 2024) – Element Biosciences, Inc., developer of pioneering technologies to empower science, will present details on five new products launching in 2024 at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.

With the introduction of AVITI²⁴, Cloudbreak UltraQ, Trinity, Cloudbreak Freestyle and Expert Mode HD, Element is shifting the paradigm for sequencing by adding groundbreaking multi-omics capabilities to its AVITI System, while reaching a new level of quality and ease of workflow.

AVITI²⁴ is the first device capable of analyzing multiple biological signals simultaneously, allowing researchers to analyze DNA, RNA, proteins, phosphorylated proteins, and cell morphology from multiple perspectives and points in time in the same run under 24 hours. Never before have so many data points been available to researchers at this cost and speed.

Cloudbreak UltraQ is the industry’s first commercial Q50 kit capable of generating 100-fold higher accuracy than currently available published specifications. This technology will empower research investigations into cancers, rare diseases, and other complex genetic variants.

Trinity is Element’s on-board enrichment solution that simplifies targeted sequencing, to provide users with a new level of convenience, flexibility, and performance.

Cloudbreak Freestyle is designed to reduce hands on-time and is directly compatible with >95% of library preparation kits on the market.

Expert Mode HD is designed to reduce costs and generate 20-70% more reads per run.

"The Cloudbreak Freestyle sequencing kits are fantastic. The new, streamlined workflow enabled us to directly load Illumina libraries onto the AVITI, producing sequencing reads of high quality that outperformed the Illumina NovaSeq,” said Rob Mitra, PhD, Alvin Goldfarb Distinguished Professor of Computational Biology at Washington University in St. Louis. “We've been extremely pleased with the performance of our AVITI instrument.”

Element will speak to the shift in science made possible by these new products and what it means for researchers around the globe at their workshop “Future Unveiled: ABC and AVITI – Opening a Gateway to the Next Evolution of Sequencing” on Wednesday, February 7, at 12:05 p.m. in the Grand Sierra Ballrooms D & E. In addition, Element will present six posters spanning applications as diverse as agriculture and leukemia research and share six in-suite presentations detailing their new applications. These in-suite presentations will cover Q50 and informatics, multi-omics, and workflow improvements. A full list of talks and posters is available here: https://www.elementbiosciences.com/events/meet-element-biosciences-at-agbt-2024

“AVITI²⁴ drives rapid, iterative learning for systems biology studies for DNA, RNA, proteins, phosphorylated states, and morphology -- simultaneously on the same instrument,” said Michael Previte, PhD, Chief Technology Officer, SVP of R&D, and Co-Founder of Element Biosciences. Multi-modal studies today require complex workflows over multiple days with highly trained personnel across multiple instruments. AVITI²⁴ streamlines these studies and data collection to enable rapid recursive learning with broad applications across systems biology. With advances in AI modeling and AVITI²⁴ multimodal data, we hope to further push back the veil on the mysterious rules that govern our biological systems."

“AVITI²⁴ allowed us to quantify the expression levels of many genes in a large field of view where the endothelial cells are experiencing different flow patterns at any location in a complex hemodynamic environment,” said Dayu Teng, PhD, Co-Director of the Whitaker Institute for Biomedical Engineering at UC San Diego. "The integration of regional genomic and proteomic quantification at a subcellular resolution, with a large field-of-view, and the flexibility in selecting substrates, forms a unique platform technology that empowers us to tackle numerous vascular bioengineering studies that were once deemed impossible.”

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Announces Expanded Customer Base, New Products, and Unprecedented Capabilities on a Benchtop Sequencer

2024-01-08T17:30:00-08:00

Element has exceeded 160 orders, generating more than $25 million in revenue in 2023
Element announces roadmap for suite of new products in 2024

SAN DIEGO, Jan. 8, 2024 /PRNewswire/ – Element Biosciences, Inc., developer of pioneering technologies to empower science, has received over 160 commercial orders of its AVITI benchtop sequencer and expanded its installed base to 112 instruments, the company announced today at the J.P. Morgan 42nd Annual Healthcare Conference. Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023. Looking ahead, the company also shared a roadmap for new products launching in 2024, including multi-omics capabilities that make AVITI an integrated biology platform.

Today’s announcement confirms that Element’s core technology is capable of much more than sequencing, opening up new and more direct paths into multi-omics analyses to make these areas of research even more accessible and cost effective for scientists. The innovations announced today will further the company’s mission to empower scientists around the globe to drive their research forward with integrated insights delivered through parallel molecular analysis. Element CEO and Co-founder Molly He presented on the following updates to AVITI at JPM:

Expert mode HD –Enhanced output options. An instrument option that allows users to generate 20 to 70 percent more reads per run from all sequencing kits. This advanced feature reduces sequencing costs to under $1 per million reads – improving costs for many applications including single cell sequencing.
Cloudbreak Freestyle – Maximizing compatibility and ease of use. A new sequencing kit that is directly compatible with more than 95 percent of library preparation kits on the market. Freestyle eliminates library conversion steps and streamlines AVITI sequencing with a wide diversity of library types, saving valuable time and effort.
Cloudbreak UltraQ – The first commercial Q50 kit. Element continues to set the industry standard for high quality sequencing. With Cloudbreak UltraQ, researchers gain access to unmatched accuracy that is 100-fold higher than available methods. UltraQ empowers investigations requiring the highest sequencing accuracy and coupled with the standard features of the AVITI platform, provides insights into complex genetic variants and challenging regions of the genome.
Trinity – New on-flowcell library workflows. Trinity spearheads Element’s efforts to comprehensively support on-board sample preparation. This innovation simplifies targeted sequencing, including exome sequencing, to a simple, on-flowcell workflow and creates a new level of convenience, flexibility, and performance.
AVITI24 – Sequencer meets cellular decoder. Leveraging the superior avidite base chemistry, the AVITI24 will be the first instrument to combine its state-of-the-art sequencing capabilities with the simultaneous measurement of multiple analytes, including DNA, RNA, proteins, phosphorylated proteins, and cell morphology, at unparalleled speed and output. This transformative capability allows scientists to analyze data from multiple time points within biologically relevant signaling pathways or analyze multiple drug concentrations or any combination of these measurements from the same run in under 24 hours.

“When we launched AVITI in 2022 we redefined what is possible on a benchtop sequencer, offering an unprecedented combination of accuracy, speed, and cost. Today, we are once again raising the bar for the industry,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “These changes mean that scientists across the world will spend less time resource planning and more time analyzing meaningful data with the potential to impact our lives for the better.”

Prominent scientists articulated how the novel capabilities are poised to expand the horizons of our understanding of biology.

“It’s thrilling to see the level of innovation Element is bringing to the field,” said Sarah Teichmann, PhD, Head of Cellular Genetics at the Wellcome Sanger Institute. “The new capabilities in multi-omics can help cell biologists by integrating molecular analysis into the samples that we study, thus re-defining human cell biology at unprecedented depth and resolution. Element continues to create products that transform what a sequencer can do and help scientists around the world unleash their creative potential.”

“Images are incredibly rich in information, and it is very exciting to see Element innovating to integrate cell morphology with precise molecular measurements,” Emma Lundberg, PhD, Associate Professor of Bioengineering and Pathology at Stanford University. “I believe that we’ll be able to more accurately resolve transient cell phenotypes and states by capturing both types of information simultaneously."

"The ability to sequence DNA and RNA directly in cellular systems is extremely exciting, as it would enable applications such as cellular morphology-based phenotyping after CRISPR perturbation, the analysis of allele-specific expression in a cell-specific fashion, and the cell-based analysis of alternatively spliced gene isoforms,” said Robi Mitra, PhD, Alvin Goldfarb Distinguished Professor of Computational Biology at Washington University in St. Louis.

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
kristi.heim@elembio.com

Element Biosciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

2023-12-19T05:00:00-08:00

SAN DIEGO, CA (December 19, 2023) – Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced that Element CEO and Co-Founder Molly He will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 8, 2024, at 5:00 PM PST / 8:00 PM EST.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing technology for research markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic research. To learn more about Element, please visit www.elementbiosciences.com.

Media Contact:

Element Biosciences
Kristi Heim
kristi.heim@elembio.com

Element Biosciences Welcomes William P. Donnelly to its Board of Directors

2023-11-21T04:00:00-08:00

SAN DIEGO, CA (Nov. 21, 2023) – Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced that William (Bill) P. Donnelly has joined its board of directors.

Mr. Donnelly spent more than 20 years growing the international instrumentation firm Mettler-Toledo International Inc. and currently serves as lead independent director at Ingersoll Rand Inc. and on the boards of T. Rowe Price and Quanterix Corporation. While at Mettler-Toledo, he oversaw the company’s transition from a leveraged buy-out to an IPO to a highly successful public company.

“Bill is joining our team at the perfect time as Element enters the next chapter of growth,” said Molly He, CEO and Co-Founder of Element Biosciences. “Bill’s experience is a huge asset to our team as we continue our innovation and expand access to the highest quality tools for biology.”

“Molly and her co-founders have built an unstoppable team of scientists and business leaders on top of a transformational technology. I am delighted to be joining the board and to further Element’s mission to empower the scientific community and accelerate the field of genomics,” Bill Donnelly said.

About Element Biosciences, Inc.

Media Contact:

Element Biosciences
Kristi Heim
kristi.heim@elembio.com

QIAGEN and Element Biosciences Partner to Offer Complete Next Generation Sequencing Workflows for the AVITI System

2023-11-02T05:00:00-07:00

Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis
Element and QIAGEN are advancing genomic applications with innovative technology and complete next-generation sequencing (NGS) workflows for researchers
Partnership to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific community

VENLO, the Netherlands, and SAN DIEGO, Ca. -- Nov. 2, 2023 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element Biosciences, Inc. today announced a strategic partnership to offer comprehensive next-generation sequencing (NGS) workflows for the AVITI™ System, an innovative sequencing platform based on Element’s novel Avidity sequencing chemistry.

Element’s AVITI System, a flexible benchtop sequencer with industry-leading performance and cost, delivers high quality, affordable data for any application, at a range of scale. For customers using the AVITI System, QIAGEN provides Sample to Insight NGS workflows with validated QIAseq panels and integrated bioinformatic solutions, including CLC LightSpeed and QCI Interpret software.

“The collaboration between QIAGEN and Element Biosciences delivers unprecedented insights across various genomic applications to our customers worldwide. Researchers are increasingly searching for complete solutions and workflows from sample to insight, and we are committed to advancing the field together by providing innovative technology and applications that help researchers accelerate discovery,” said Nitin Sood, Senior Vice President, Head of Life Sciences Business Area at QIAGEN.

Yaron Hakak, PhD, Senior Vice President of Corporate and Business Development at Element Biosciences, added: “Element and QIAGEN share the goals of offering flexible, cost-effective, and high-performance solutions to our customers. Jointly promoting the combined workflow will help us serve an expanded customer base with the backing of a global genomic powerhouse like QIAGEN.”

QIAGEN’s QIAseq panels enable efficient and accurate NGS library preparation. The QIAseq miRNA Library Kit, the QIAseq xHYB Actionable Exome Panel, and the QIAseq Targeted DNA Pro Panel have been validated on the AVITI sequencer with robust performance, high specificity, and coverage uniformity, as well as consistent variant detection.

LightSpeed, a new module for QIAGEN CLC Genomics Workbench Premium, enables AVITI System users to perform cost-effective whole genome sequencing (WGS) secondary analysis with exceptional runtimes. QCI Interpret, a fully customizable software solution, facilitates NGS variant interpretation and reporting for oncology and hereditary applications, with over 3 million reports issued.

“There is a huge potential for NGS to deliver on the vision of precision medicine. One of the greatest barriers to ubiquitous adoption and use is the efficient downstream analysis and interpretation of processed samples,” said Jonathan Sheldon, PhD, Senior Vice President of QIAGEN Digital Insights. “We are pleased to partner with Element Biosciences to deliver joint solutions that enable customers to rapidly adopt, automate, and scale their NGS needs with higher cost efficiencies and faster turnaround times.”

More information on the NGS workflow for the AVITI system can be found here: https://www.elementbiosciences.com/products/aviti

Element will present new data from customers and highlight AVITI’s higher accuracy sequencing for research applications at the American Society of Human Genetics (ASHG) 2023 annual meeting. More information: https://www.elementbiosciences.com/events/meet-element-at-ashg-2023

About Element Biosciences, Inc.

Element Biosciences Media Contact:

Kristi Heim
kristi.heim@elembio.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts QIAGEN:

Investor Relations		Public Relations
John Gilardi	+49 2103 29 11711	Thomas Theuringer	+49 2103 29 11826
Phoebe Loh	+49 2103 29 11457	Daniela Berheide	+49 2103 29 11676
e-mail: ir@QIAGEN.com		e-mail: pr@QIAGEN.com

Element Biosciences to Present at ASHG 2023

2023-10-19T04:00:00-07:00

Element will share details on its novel sequencing methodology and host a workshop on higher accuracy sequencing for improved variant detection

SAN DIEGO, CA (October 19, 2023) – Element Biosciences, Inc., developer of the Element AVITI^™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, will present new data from customers in oncology and immunology and highlight AVITI's higher accuracy sequencing for research in rare and undiagnosed genetic disease and other research applications at the American Society of Human Genetics (ASHG) annual meeting on Nov. 1-5, 2023, in Washington D.C.

Data generated on the AVITI platform will be featured in a poster by Phase Genomics on next generation cytogenomics, where Hi-C DNA sequencing has the potential to provide data in one workflow that currently requires multiple distinct assays. This is important for labs because workflow consolidation has the potential to simplify lab operations, reduce costs, and use limited samples more efficiently. In addition, running OncoTerra on the AVITI could speed turnaround time, as fewer samples can be batched while still meeting cost targets.

Element, a silver sponsor of ASHG 2023, will be at Booth 1223 to introduce its products and applications, including its $200 genome program, as well as a new grant program, the AVITI Accelerator Grant, in partnership with co-sponsor AUGenomics.

Element will also share results from a research study with the Translational Genomics Research Institute (TGen), part of the City of Hope, that identified the likely genetic causes of neurological disorders in children. The findings were recently posted to medRxiv.

Using AVITI, the research study leveraged a novel design of sequencing the parents at half the coverage of the child so that the entire trio could be sequenced on a single flow cell, while retaining the ability to identify de novo variants. The sequencing, which took under 48 hours to complete, and cost $1,680 per trio, was performed by FYR Diagnostics, a service provider and early Element customer. With its new Cloudbreak chemistry, Element has further reduced the runtime to 38 hours.

"At ASHG, we are excited to share examples of how the AVITI system is igniting the next round of genomics discovery with high quality, affordable data for any application, at any scale," said Shawn Levy, PhD, CTO and SVP of Applications at Element Biosciences. "And we are only at the beginning with Avidity sequencing, with clear paths to continued gains in performance and capabilities."

Customers are responding to the exceptional quality AVITI is bringing to their projects.

"We are a service lab, so the argument that the quality we can promise is better than we can provide with other sequencers makes it much, much easier to convince our clients that they are in good hands with the sequencing," said Lutz Froenicke, PhD, director of the DNA Technologies and Expression Analysis Cores at the UC Davis Genome Center. "What personally impresses me is that the company came up with a sequencing chemistry that is so different from anything else, and it works amazingly well."

Highlights:

Platform Talk: Thursday, Nov. 2, 1:45 – 2:00 PM
Patrick Kennedy, Research Technician, Samuel A. Myers Lab at the La Jolla Institute for Immunology
"Discovery of novel signaling-to-transcription networks in T cell activation coupling base editor screens with single cell multiomics"

Poster presentations: Thursday, Nov. 2, 3:00 to 5:00 PM ET

Stephen Eacker, PhD, Vice President of Research and Development at Phase Genomics
"Next-generation cytogenomics using proximity ligation technology on the AVITI genome sequencing platform"

Semyon Kruglyak, PhD, VP of Informatics, Element Biosciences
"An efficient design for whole genome trio sequencing identifies causal variants in rare neurological disorder cases"

Lunch Workshop: Friday, Nov. 3, 12:30 – 1:30 PM ET

Speakers:

Keri Ramsey, BSN, RN, Clinical Co-Director, Center for Rare Childhood Disorders, TGen
"An efficient design for whole genome trio sequencing leads to high diagnostic yield in rare neurological disorder cases"
Semyon Kruglyak, PhD, VP of Informatics, Element Biosciences
"Accurate human genome analysis with Element Avidity sequencing"

About Element Biosciences, Inc.

Element Biosciences Media Contact:

Kristi Heim
Element Biosciences
kristi.heim@elembio.com

Revvity and Element Biosciences Announce Collaboration to Improve Next Generation Sequencing Research Workflow

2023-10-16T03:00:00-07:00

Next generation sequencing workflow with research use only components from both companies is designed to provide flexibility, time and cost savings on sample-to-answer solutions
Neonatal research applications have been identified as a focus area
Laboratory needs can be addressed with turn-key solutions or modular components

WALTHAM, Mass. and SAN DIEGO, Ca. -- October 16, 2023 -- Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

“This collaboration between Revvity and Element Biosciences seeks to elevate the overall customer experience by providing compelling application-specific data, stronger support and easier access to the critical components necessary for a lab to go from sample to result,” said Arvind Kothandaraman, general manager of multi-omics and specialty diagnostics at Revvity. “By addressing the typical workflow-related challenges faced by labs, we are accelerating the democratization of genomic sequencing.”

“Working with Revvity will allow us to greatly expand the reach of high-quality sequencing as part of a complete solution for the benefit of customers everywhere,” said Yaron Hakak, SVP of corporate and business development at Element Biosciences.

Genomic data generated by next generation sequencing (NGS) plays an increasingly important role in scientific innovation and research. The NGS process encompasses a series of detailed steps, including sample collection and processing, nucleic acid extraction, library preparation, quality control, sequencing, data analysis and integration into laboratory information management systems. This process can be daunting, especially for labs that are new to NGS and are considering routine use of genomic sequencing data. This data is crucial to driving research into human health improvements as reflected in research publications and ongoing studies in many disease identification efforts, including neonatal research applications.

Revvity offers carefully curated research use components, spanning the NGS continuum around the sequencing platform. These offerings include sample collection devices, a DBS puncher for punching dried blood spot samples, chemagic™ kits and instruments for automated nucleic acid extraction, a wide range of liquid handlers and reagent kits for automated library preparation, the LabChip® GX Touch HT nucleic acid analyzer and VICTOR2™ D Instrument for sample quality control, and software capabilities that are vital for data management and interpretation. For labs interested in a service model, Revvity Omics, Inc., provides end-to-end solutions from delivery of a sample collection kit to final report, providing the flexibility to access sequence data only or report only to augment the customer’s in-house capabilities.

When it comes to the NGS platform itself, data quality and flexibility play a pivotal role in determining a lab’s choice for advancing research. The Element AVITI System, a flexible benchtop sequencer with industry-leading performance and cost, delivers high quality, affordable data for any application, at a range of scale. Element’s AVITI System is quickly gaining broader adoption, exceeding 100 commercial orders from customers across the globe. Earlier this year, Element Biosciences announced a new throughput-based option for its AVITI System that provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase. Revvity Omics has recently adopted Element’s AVITI platform for its global service business, demonstrating improved technology capabilities, flexibility and speed.

Revvity and Element Biosciences plan to make the combined solution available to an expanded customer base interested in the full workflow or specific modules. Laboratories interested in discussing their research needs can do so via this dedicated channel.

About Element Biosciences, Inc.

Element Biosciences Media Contact:

Kristi Heim
Element Biosciences
kristi.heim@elembio.com

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity Media Contact:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Element Biosciences Announces Over 100 Commercial Orders of its AVITI System and Surpasses Q2 Sales Goals

2023-09-06T04:00:00-07:00

Business momentum propelled by U.S. and international expansion

SAN DIEGO, CA (September 6, 2023) – Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced it has exceeded 100 orders of the AVITI System. With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks. The company has seen triple digit quarter-on-quarter growth since launch, and in Q2 reached an estimated 15 percent of the total sales of mid-throughput sequencing instruments, just one year after its first commercial shipments. Element has also signed distribution agreements with 11 distributors across the globe.

“Today’s milestone validates the market demand for truly differentiated solutions that help customers achieve more with sequencing, regardless of scale. It is the result of years of hard work by the pioneers at Element, and a strong testament to the creativity, commitment, and grit of our highly effective team across the entire company,” said Molly He, PhD, CEO and Co-Founder of Element Biosciences. “As a data-driven company, we are committed to setting ambitious goals and consistently delivering data and outcomes that surpass expectations. This is only the beginning.”

Customers around the world are responding to Element’s industry-leading data quality, flexibility, and exceptional customer support. Consistently innovating with new technology, Element has disrupted the market with a system that delivers unprecedented performance and quality, regardless of scale. This year, Element introduced the $200 Genome, followed by the launch of Cloudbreak™, enhancements to its chemistry that reduce run times, increase accuracy, and enable even more applications, and a suite of genomic tools, known as the AVITI FIT for even greater flexibility. These innovations underscore Element’s unparalleled data accuracy validated in multiple studies, most recently by Andrew Carroll and a team at Google in this BioRxiv preprint.

“We have been very excited by the interest of the scientists we support for the AVITI chemistry. We have many labs that are particularly intrigued by both the cost effectiveness of the platform as well as the very high quality of the reads, which we hope will help us aggressively advance down numerous research paths that are currently poorly supported by the dominant platforms,” said Stuart Levine, PhD, BioMicro Center Director, Massachusetts Institute of Technology.

“Our ability to deliver timely, cost-effective sequencing results is critical,” said Dr. Madhuri Hegde, FACMG, SVP and Chief Scientific Officer of Revvity, which maintains a global network of laboratories to offer innovative, omics-based services to customers in more than 155 countries worldwide. “Element's AVITI system has provided the improved technology capabilities, flexibility, and affordability to support our ability to positively impact human health around the globe.”

“The AVITI system from Element has lived up to its expectations -- the highest quality NGS sequencing backed by a proactive support team for troubleshooting, protocol development and technical issues,” said Derek Warner, Director, DNA Sequencing Facility at the University of Utah.

New customers using AVITI span a range of industries, including large genome centers and core labs, biotech companies, government, pharma, and academic labs, using a wide variety of applications in their research. In addition, 80 percent of these customers were experienced users upgrading to the AVITI platform. Over 40 percent of sales were multi-unit orders and Element also welcomed repeat customers adding capacity to their existing fleet of AVITI instruments.

In Asia, customer Burning Rock Dx, a biotechnology company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, purchased multiple AVITI instruments after conducting rigorous and extensive validation work to support its research activities.

“The data quality of Element gave us a lot of confidence, as we saw improved sequencing accuracy, better genome coverage, lower duplication rates, and better performance in difficult genomic areas such as homopolymer region,” said Dr. Joe Zhang, CTO of Burning Rock Dx. “This can help us further improve the performance of oncology research products and continue to strengthen our technological leadership.”

In Europe, Element and partner EMBL (the European Molecular Biology Laboratory) are featuring AVITI in a new course on the latest state-of-the-art sequencing platform technology and novel library preparation protocols, November 6 to 9 in Heidelberg, Germany.

“For us, the AVITI system could represent a game changer in several dimensions – it fills important gaps with respect to throughput, flexibility, and accuracy, and this comes with an astonishing low price tag,” said Christian Thiede, M.D., CEO/CMO of AgenDix GmbH, a provider of sequencing services in Germany.

Helixio, a genomic and bioinformatics service provider with the first AVITI System in France, has been using AVITI consistently for a wide variety of applications, including RNAseq, scRNAseq, whole genome sequencing, metagenomics, and epigenetics.

“Flexibility, fast turnaround time, high-quality data and efficient technical support are key to our success, and the AVITI sequencer delivers,” said Véronique Vidal, president of Helixio. “It shows both compatibility with our library preparation workflows as well as easy integration with our existing bioinformatics pipeline, making it an easy transition for us.”

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Adds Genomics Executive to Leadership Team to Accelerate Corporate Development

2023-08-24T04:00:00-07:00

Yaron Hakak brings over 20 years of experience in new products, technologies, and commercial partnerships

SAN DIEGO, CA (August 24, 2023) – Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the appointment of veteran life science executive Yaron Hakak as Senior Vice President of Corporate and Business Development.

As Element grows its commercial organization, Yaron will lead business and corporate development to accelerate the company’s global growth through high impact business and strategic partnerships, joint ventures, and acquisitions.

“I’m thrilled to welcome Yaron to Element as we continue to expand around the world with tools to advance scientific discoveries,” said Molly He, Ph.D., CEO and Co-Founder of Element Biosciences. “With his experience and stature in the industry, Yaron will play a pivotal role as we develop more strategic partnerships and drive adoption of both the AVITI System and Element’s future products.”

Yaron was most recently CEO of Jumpcode Genomics, where he scaled the organization from inception to a commercial organization with multiple product offerings. Prior to Jumpcode, Yaron was a Director of Corporate and Business Development at Illumina, where he led a team that supported the company’s life science, applied markets, and international businesses. Before that, he served as Director of Business Development at Affymetrix, where he supported corporate activities related to its genomics and proteomic product portfolios.

Yaron earned a Ph.D. in Molecular Biology from the University of California, Berkeley, and a B.S. in Biophysics from the University of California, San Diego.

“I am honored to join the Element team to help further the development and worldwide adoption of the AVITI sequencing platform,” said Yaron Hakak. “It’s an exciting time in next-generation sequencing as technological advancements enable existing and new applications. Element’s unique capabilities allow for the continued introduction of innovative solutions to address customer needs. I look forward to forging new partnerships to accelerate the company’s growth.”

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Announces AVITI™ FIT, a Suite of Products to Empower More Researchers with Flexible Genomic Solutions

2023-08-17T04:00:00-07:00

New options expand the benefits of AVITI to fit an even wider range of customers and applications

SAN DIEGO, August 17, 2023 – Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today unveiled five new products to better serve customers’ low to medium-throughput needs and expand the functionality and versatility of its benchtop sequencer.

As more researchers are turning to genomics and the needs of labs across the world are evolving, this new product suite will bring AVITI’s industry leading technology to an even wider range of customers, including those who need more operational flexibility, less throughput, or access to longer read applications.

These products, which are available now, include:

AVITI LT (Low Throughput): An alternative version of the AVITI System that runs the low and medium throughput sequencing kits. AVITI LT brings Element’s high-quality sequencing with Cloudbreak™ chemistry to more users by lowering instrument cost and can later be upgraded to a full-throughput AVITI.

Individually Addressable Lanes: Flexibility to isolate libraries to a single flow cell lane and seamlessly process two libraries per flow cell without additional time, kits, or reagents.

Flexible Throughput Kits: New versions of our kits to enable customers with small sample batches or targeted panels to take control of their samples and timelines by running cost-effective low and medium output kits while still enabling individual lane loading for even more flexibility.

2x300 bp Sequencing Kits: Our industry-leading chemistry enables the highest quality and lowest cost solution to enable more applications to take advantage of cost-effective read lengths up to 2x300.

Elembio™ Cloud: An online platform for managing instruments, monitoring runs with real-time updates, and visualizing run metrics and data to gauge run performance.

“A more versatile mix of flow cell capacities on the AVITI means we can migrate almost all of our routine sequencing activities - NGS services, product QC, and R&D - to a single instrument and workflow without the logistics issues of complicated batch management,” said Jacob Enk, Ph.D., Director of Research, Development, and Applications at Daicel Arbor Biosciences. “This relieves routine headaches for us and allows us to concentrate more on answering important research questions.”

“Element is continuously innovating to expand access to high quality, affordable, on-demand sequencing to more customers, including labs that have lower throughput needs, run applications that require longer read lengths, or have limited CapEx budget,” said Francisco Garcia, PhD, SVP of Informatics at Element Biosciences. “With these new products, whatever your genomics needs are, the AVITI System is always the perfect fit.”

This news comes on the heels of a series of key innovations for Element in the year since launching the AVITI System. In June, Element launched Cloudbreak, improvements to its chemistry that reduce run times, increase accuracy and enable even more applications. In May, Element announced its partnership with Amazon Omics to provide simple, powerful, and cost-effective analysis workflows. In January, Element announced a new throughput-based option for its AVITI System that provides the highest quality sequencing on a benchtop for as low as $200 a genome.

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Establishes Scientific Advisory Board

2023-08-14T04:00:00-07:00

Leading Scientists from Stanford, University of Chicago, and Wellcome Sanger Institute Strengthen Element’s R&D Expertise and Innovation Engine

SAN DIEGO, CA (August 14, 2023) – Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.

Element’s Scientific Advisory Board will provide guidance and direction for research, development, and product innovation as the company continues its success and expansion in the genomics industry. The initial SAB members are:

Tanja Andrea Gruber, MD, PhD, Chief of Pediatric Hematology Oncology Stem Cell Transplant and Regenerative Medicine at Stanford University. Dr. Gruber also serves as the Director of the Bass Center for Childhood Cancer and the Associate Director for Childhood Cancer at the Stanford Cancer Institute.

Chuan He, PhD, the John T. Wilson Distinguished Service Professor in the Department of Chemistry, Department of Biochemistry and Molecular Biology at the University of Chicago. He is a winner of the 2017 Paul Marks Prize for Cancer Research and 2023 Wolf Prize in Chemistry.

Joseph (Jody) Puglisi, PhD, (SAB Chair), Jauch Professor in the Department of Structural Biology at Stanford University School of Medicine, where his work focuses on the biophysical and structural analysis of RNAs and RNA-protein interactions. He is a member of the U.S. National Academy of Sciences.

Sarah Teichmann, PhD, systems and genome biologist and head of the Cellular Genetics Programme at the Wellcome Sanger Institute, Cambridge. She is also Director of Research at the Physics Department at the University of Cambridge, an elected EMBO Member, Fellow of the Academy of Medical Sciences, and Fellow of the Royal Society.

"With this diverse and accomplished group of scientists from across the globe, our Scientific Advisory Board empowers us to reach new heights in research and product innovation,” said Michael Previte, PhD, Element CTO, SVP of R&D, and co-founder. "With the support of our SAB, we are committed to providing high quality tools that allow scientists to perform affordable research and rapid discovery. Together we hope to accelerate the scientific community’s ability to pioneer groundbreaking advancements that unravel the complexities of biology.”

“I am thrilled to lead Element’s Scientific Advisory Board,” said Joseph (Jody) Puglisi, Jauch Professor in the Department of Structural Biology at Stanford University School of Medicine and Element’s Scientific Advisory Board chair. “I have watched with deep respect as the team developed the initial sequencing technology, with an eye on low cost and high quality. I am particularly excited about extending the fantastic Element platform to multi-omics, realizing a vision of quantitative biology so critical for the future of medicine and biosciences in general.”

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences and Agilent Technologies Expand Partnership

2023-08-08T04:00:00-07:00

Expansion will accelerate advances in genome sequencing and analysis

SAN DIEGO, CA (August 8, 2023) – Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced an expanded commercial partnership with Agilent Technologies to cooperate in selling Element and Agilent products, starting in the United States.

This partnership builds on a co-marketing agreement the companies entered last year demonstrating the integration of Element’s AVITI System and Agilent’s industry leading SureSelect target enrichment panels. It opens greater commercial reach for Element’s AVITI System and improved user experience of Agilent’s SureSelect portfolio. Agilent and Element will promote, market, and provide training on each other’s products.

“We are excited to collaborate with Agilent to bring AVITI’s unbeatable quality and flexibility to users of Agilent’s SureSelect sequencing panels and reagents,” said Logan Zinser, Senior Vice President of Finance at Element Biosciences. “This next step in our partnership with Agilent helps expand the reach of these genomics tools to more customers and offer exceptional value and performance.”

“Following the successful co-marketing agreement with Element, we are expanding our collaboration to offer more customers the combined benefits of the AVITI platform with our trusted and proven SureSelect Solution,” stated Kevin Meldrum, Vice President and General Manager for Agilent’s Integrated Genomics Division. “Our partnership will continue to accelerate adoption of this powerful tool to meet the demand for fast, cost-effective, and accurate sequencing and genome analysis.

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Announces Genomics Industry Veteran as Senior Vice President of Marketing and Product Management

2023-07-13T04:00:00-07:00

Edwin Hauw brings over 20 years of marketing and product management experience to Element as the company expands to provide genomics tools for researchers around the world

SAN DIEGO, CA (July 13, 2023) – Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the appointment of Edwin Hauw as senior vice president of marketing and product management.

“The genomics industry is at a crucial inflection point, and Element has brought innovative technologies to cutting-edge labs across the world,” said Molly He, Ph.D., CEO and Co-founder of Element Biosciences. “We look forward to leveraging Edwin’s world-class genomics expertise and seasoned leadership as we continue Element’s success and expand AVITI’s presence in the market.”

As senior vice president of marketing and product management, Edwin will work along with the leadership team to evolve, guide and manage product strategy, strategic marketing, field marketing and product management. He will help to nurture and develop external partnerships and implement strategies for positioning and driving the adoption of both the AVITI system and Element’s future products in the marketplace.

Edwin was previously 10x Genomics’ vice president of marketing, leading product management and marketing and growing the business by 20x within his six years. Prior to 10x Genomics, Edwin was Pacific Biosciences’ senior director of product management, leading the launch of the world’s first long-read single molecule sequencer, the PacBio RS, along with the RS II and Sequel System. His earlier roles include product management at Applied Biosystems, Affymetrix and Biodiscovery.

Edwin completed his Master of Business Administration in Finance and Marketing from the University of Southern California. He received his bachelor’s in biology and psychology from the University of California, San Diego.

“I know firsthand how important it is to bring researchers technologies that make their R&D efforts easier and more affordable,” said Edwin Hauw. “I’m honored to join the Element team and introduce the AVITI system to more labs and see its world-changing applications across industries – from agriculture to healthcare and more.”

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Michael Galfetti
Mission North
elementbiosciences@missionnorth.com

Novel Genetic Sequencing Technology Helps Researchers Find Answers in Cases of Pediatric Rare Disorders

2023-07-10T04:00:00-07:00

The study identified likely cause of genetic disorder in six families

PHOENIX, AZ and SAN DIEGO, CA— July 10, 2023 — A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora, Mexico. These research results have been independently confirmed in a clinical lab setting.

The findings will help these children and their families, who had little or no access to previous genetic testing, as they seek treatments and supportive communities.

The children in the study have conditions including developmental delay, problems with language, seizures, heart anomalies and other difficulties, said Keri Ramsey, BSN, Clinical Co-Director of TGen’s Center for Rare Childhood Disorders. For one of the conditions identified, there are treatment options available. For a second condition, there are research studies in gene therapy underway.

“Having an answer will give these families hope and access to resources that maybe they weren’t eligible for in the past and can help their child’s physician make adjustments to the patient’s care and management of their symptoms,” said Meredith Sanchez-Castillo, M.D., Clinical Research Coordinator at TGen’s Center for Rare Childhood Disorders.

TGen researchers worked with Element Biosciences, a multidisciplinary life science company and its AVITI™ benchtop sequencer, to sequence the genome from each child and their parents in nine families. Through cost and workflow improvements, Element’s technology will support broader access to genetic testing for families like the ones in this study.

TGen and Element researchers will present the results of the Sonoran study at the American Society for Human Genetics meeting in November 2023.

“These families come from Sonora, Mexico, with limited resources and no access to genetic testing,” said Sanchez-Castillo, who worked with clinicians in Mexico to identify the families. “Some of the families required temporary visas to enter the U.S. which makes things more complicated for them since they have to drive more than five hours to our clinic.”

Genetic sequencing of the trio, a child and both parents, can uncover genetic variants that might be related to the child’s disorder, and whether those variants are inherited. During this process, each part of the DNA is sequenced multiple times, and how often it is sequenced is called coverage.

The study leveraged a novel design of sequencing the parents at half the coverage of the child so that the entire trio could be sequenced on a single flow cell, while retaining the ability to identify de novo variants.

“This design of a trio per flow cell is fast, cost effective, and obviates the sample batching required for factory scale systems. We were excited to see that it was also highly effective in identifying inherited and de novo variants of interest,” said Semyon Kruglyak, Ph.D., Vice President of Informatics at Element Biosciences.

Kruglyak and his colleagues had tested the technology on a rare early onset blindness condition and wanted to expand the study to see how well it might work in finding new or “de novo” genetic variants that aren’t inherited from parents, but instead show up first in the child. Such variants more commonly occur in neurological disorders.

At roughly 40 times coverage for the child and 20 times coverage for each parent, the sequencing took under 48 hours to complete, and cost $1,680 per trio. Each Element AVITI instrument accommodates two flow cells, so two trios can be sequenced at a time. The sequencing for this study was performed by FYR Diagnostics, a service provider and early Element customer.

“I think this is significant, especially for bringing the technology to these researchers,” said June Zhao, Ph.D., Senior Director of Applications at Element Biosciences, who noted that the process uses off-the-shelf library prep products to generate PCR-free libraries for AVITI sequencing. “It’s simple and easy to use, has a faster turnaround time, and we can achieve high quality with the benchtop sequencer.”

Even with the lower coverage for parents, the researchers were able to identify the likely genetic cause in 67% of the families. “Usually, our rate of detection for families in the Center is around 40%,” said Ramsey.

TGen and Element researchers independently analyzed the results, and “we had near perfect concordance, so I think that’s a testament to the data quality and the interpretation processes that were utilized to draw conclusions,” said Kruglyak.

The affected gene was different in all families, and the technology was able to capture a variety of different kinds of gene variants, he added.

“Following clinical confirmation, we have started counseling the six families about family planning and recurrence risk,” Ramsey said. In cases where no current treatment is available, the Center will help the families connect with resources and other patients with the same condition.

“Not only does this have the potential to explain what the cause is of their child’s symptoms, it may also provide insights on what the future might hold for their children,” she added.

Ramsey said that since TGen’s Center for Rare Childhood Disorders opened in 2012, it has become more important than ever to seek genetic diagnoses.

“A lot of the therapeutic approaches now are leaning toward gene therapy—going in and editing or providing copies of the missing or broken gene. In these cases, it’s vital to know the underlying genetic cause of the child’s disorder,” she said. “At TGen we’re always looking for the best types of sequencing technologies, and this is really exciting because it’s a proof of concept that this sequencing strategy is successful.”

About TGen, part of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process. Follow TGen on Facebook, LinkedIn and Twitter @TGen.

Media Contact:

Galen Perry
602-343-8423
gperry@tgen.org

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Enters the European Genomics Market with New Customers and a Growing Team

2023-06-05T04:00:00-07:00

SAN DIEGO, CA, and AMSTERDAM (June 5, 2023) – Element Biosciences, Inc., the developer of the Element AVITI™ System, an innovative DNA sequencing platform disrupting genomics, is pleased to announce that the AVITI is now available in Europe, in addition to Asia and the Middle East. VIB, Flanders’ leading life science research institute in Belgium; Lexogen, a global leader in RNA sequencing; and IGA Technology Services, the leading Italian provider of genomic research services, are among the first customers who have chosen Element Biosciences’ AVITI sequencing platform to support their labs.

“We are impressed with how easy the AVITI sequencer is to operate and maintain. Its flexibility enables us to produce high quality data with fast turnaround,” said Stefaan Derveaux, manager of the Nucleomics Core at VIB. The Nucleomics Core will use the AVITI sequencer for a variety of sample types, including scRNA, bulk RNA, metagenomics and others.

A year after launching the AVITI System, Element has completed successful installations across the United States, Asia and now Europe. With the establishment of a European entity and a growing sales and support organization, Element can now support a wide variety of applications and research labs across the world. In addition, Element has continued to innovate on its modular platform including with faster run times, expanded kit offerings, the Elembio Cloud™ software platform, and industry-leading low costs while maintaining the highest quality sequencing on a benchtop.

“The sequence quality of AVITI is outstanding and the flexibility of the platform is unprecedented. Our clients, involved in pre-clinical studies, biotech R&D and plant breeding programs will largely benefit from a fast-track sequencing to accelerate their development pipelines,” said Davide Scaglione, Chief Executive Officer, IGA Technology Services. “We already tested the quality of the data in genotyping-by-sequencing experiments, single-cell transcriptomics, and metagenomics projects and assessed not only a seamless integration with current analytical pipelines but also a higher homogeneity of sequence representation compared to state-of-the-art platforms.”

“At Lexogen, we strive to provide the best quality in complex RNAseq workflows for our customers. After the initial testing of Element Biosciences’ new AVITI sequencer, we are impressed with the high quality of the read outs and the flexibility to handle complex lane mixes with different library types,” said Dr. Torsten Reda, Chief Scientific Officer, Lexogen. “The mapping statistics for libraries with homopolymers stretches (e.g., QuantSeq Reverse) are significantly higher than those seen with other machines in identical library pools.”

Element will showcase AVITI and present talks on its technology at the European Society of Human Genetics (ESHG) Conference June 10-13, 2023, in Glasgow, Scotland.

“We look forward to bringing the benefits of AVITI’s flexibility, data quality, ease of use, and excellent support team to a growing number of customers in the European market,” said Molly He, PhD, Element CEO and Co-Founder. "As Element continues to offer its transformative technologies to labs and organizations on the cutting edge of scientific discoveries, these are the first of many successful collaborations we’ll be announcing this year.”

For more information about Element’s novel sequencing chemistry, please see our paper in Nature Biotechnology.

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Paper on Avidite Sequencing Chemistry Published in Nature Biotechnology

2023-05-25T05:00:00-07:00

Sequencing by Avidity enables high accuracy with low reagent consumption

SAN DIEGO, CA (May 25, 2023) – Element Biosciences, Inc., the developer of the Element AVITI™ System, an innovative DNA sequencing platform disrupting genomics, has published a paper on its novel avidite sequency chemistry in Nature Biotechnology.

The paper details avidite sequencing and the performance improvements it directly enables, including high quality, sustained accuracy through homopolymers, and dramatically lower reagent consumption.

Element demonstrates that Avidity sequencing achieves accuracy surpassing an average of one error per 10,000 base pairs (Q40) and enables a diversity of applications that include single-cell RNA-seq and whole-human-genome sequencing. Element also demonstrates an improved ability of this chemistry to sequence through homopolymer sequences.

For more information, please see the full paper in Nature Biotechnology.
Please see our website for a list of publicly available datasets made with Element Biosciences technology.

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Biosciences Accelerates Data Discoveries with Amazon Omics

2023-05-15T04:00:00-07:00

SAN DIEGO, CA (May 15, 2023) – Element Biosciences, Inc.— developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry — announced it is now leveraging a new Amazon Omics feature, Ready2Run workflows, to provide simple, powerful, and cost-effective analysis workflows. The combination of technologies gives customers the option to stream their sequencing data from AVITI™ directly to the cloud and automatically perform subsequent analysis using Amazon Omics.

Amazon Omics is a service from Amazon Web Services (AWS) that helps remove the heavy lifting from storing, querying, and analyzing various omics data. Ready2Run workflows are a set of pre-built workflows from third-party software companies and open-source pipelines. With just a few clicks or a single API call, customers can run pre-built workflows to perform analyses such as converting base calls to FASTQ files, secondary analysis such as gene expression or variant calling, and tertiary analysis such as protein structure prediction. Ready2Run workflows are priced-per-run to give customers predictable pricing.

Element’s Bases2Fastq Ready2Run workflows on Amazon Omics enable customers to stream their sequencing data from AVITI and perform analysis on Amazon Omics. This allows customers access to scalable cloud computing, the ability to process multiple runs or samples in parallel, and the simplicity of combining multiple downstream secondary or tertiary analysis tools on a single platform, all while maintaining end-to-end control of their own data. Data security is enhanced with AVITI running on Ubuntu Core, a Linux OS.

"It was quick and easy to launch the Bases2Fastq Ready2Run workflow. We are excited to use this solution to streamline our pipelines and significantly shorten the time (and effort) between our data coming off AVITI and entering secondary analysis," said Claire Seibold, Director of Software and Data Analytics at FYR Diagnostics.

The Bases2Fastq Ready2Run workflows offer a fast and affordable sample demultiplex and FASTQ generation solution. The AVITI system's dual flow cell capacity enables sequencing of up to six human whole genomes concurrently, each sequenced to a depth of around 30x. The Bases2Fastq Ready2Run workflow enables customers to demultiplex and convert their sequencing data into FASTQ files in less than two hours after completing the run. This process costs less than 1% of the total sequencing cost. By further leveraging the various secondary analysis Ready2Run workflows available in Amazon Omics, the conversion of FASTQ files to BAM or VCF files can be performed within a similar timeframe without incurring significant additional costs.

Starting in Q3 2023, customers will also be able to use Elembio Cloud™, a new offering from Element Biosciences, to seamlessly configure orchestrating the automatic launch of Element’s Bases2Fastq Ready2Run workflows using Amazon Omics.

“AVITI on Amazon Omics brings customers a cost-effective, scalable, and straightforward sample-to-answer workflow,” said Francisco Garcia, PhD, SVP of Informatics at Element. “Providing users control over their own data is key to Element’s mission to accelerate scientific progress.” For further details on AVITI Genomic Analysis on Amazon Omics, see Element’s AWS blog post.

“We’re excited to be working with companies like Element Biosciences to offer pre-built workflows as part of the new Ready2Run feature in Amazon Omics,” said Tehsin Syed, General Manager of Health AI, AWS. “Customers can now simply bring their data and run these workflows within minutes, making analysis easier and optimizing costs with predictable pricing.”

For inquiries, please contact us here: https://www.elementbiosciences.com/contact

About Element Biosciences, Inc.

Media Contact:
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Signs Multiple Global Distributors to Bring the Power of AVITI™ to Customers Around the World

2023-04-19T04:00:00-07:00

SAN DIEGO, CA (April 19, 2023) – Element Biosciences, Inc.— developer of an innovative DNA sequencing platform that is disrupting the genomics industry — has signed distribution agreements with companies based in Israel, South Korea, Australia, and the United Arab Emirates to bring its AVITI System to more customers around the world. The strong global demand for AVITI across multiple geographies shows that labs across the world are eager for our platform, which brings them high quality, low-cost, easy-to-use genomics tools that accelerate discovery.

For Israel and Palestine, Element has signed a non-exclusive distribution agreement with Eldan Electronics Instruments Ltd., a member of the Neopharm Group and one of the most experienced distributors in the Israeli medical devices and life science industries.

For South Korea, Element has entered into a non-exclusive distribution agreement with XpertGen Inc., a subsidiary of DAON BioSciences Inc., leveraging their extensive experience in the single cell market and other areas.

For Australia and New Zealand, Element has signed a non-exclusive distribution agreement with TrendBio Pty Ltd., a specialized instrument and consumable distributor servicing the Australian and New Zealand life science markets with a focus on customers in both academic and translational research and in clinical and diagnostic settings.

For Saudi Arabia and the United Arab Emirates, Element has partnered with Integrated Gulf Biosystems LLC, as its non-exclusive distributor, leveraging their extensive experience in large population studies and automation.

“We have received strong interest in AVITI from many global markets, and we are excited to partner with these experienced distributors across the world to bring AVITI to more customers,” said Mark Aitkenhead, PhD, Chief Commercial Officer of Element Biosciences. “Our goal is to expand access to the highest quality, most cost-effective sequencing and empower customers everywhere to achieve breakthrough science.”

For inquiries, please contact us here: https://www.elementbiosciences.com/contact

About Element Biosciences, Inc.

Media Contact:
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples

2023-04-14T04:00:00-07:00

The Element AVITI™ System rapidly delivers high-quality, cost-effective data to accelerate cytogenomic research on Phase Genomics’ OncoTerra™ Platform

SAN DIEGO and SEATTLE (April 14, 2023) – Element Biosciences, the developer of an innovative DNA sequencing platform disrupting genomics, and Phase Genomics, Inc., a leading developer of cutting-edge genomic solutions, today released new details of their first collaboration leveraging Phase Genomics’ proprietary OncoTerra™ cytogenomics platform and the Element AVITI System for next generation sequencing (NGS). Data generated from AVITI showed improvements in several key sequencing metrics, making it an ideal technology to pair with the proximity ligation-based OncoTerra™ cytogenomics platform for cancer research.

“We’re extending the application of our core technologies into the oncology space, ensuring Phase Genomics’ next-generation cytogenomic tools deliver unparalleled precision, speed, and efficiency. We’re excited by what we’re seeing as a result of this recent work with Element,” said Ivan Liachko, PhD, co-founder and CEO of Phase Genomics. “Although OncoTerra is NGS platform agnostic, the high quality and accuracy of Element’s AVITI System make it a great option for data generation in next generation cytogenomics.”

The OncoTerra Platform paired with the AVITI System enables high-resolution cytogenomic analysis of solid-tumor samples, including archival formats, such as formalin-fixed, paraffin-embedded (FFPE) samples, that are largely unsuitable for conventional cytogenetic assays. Data generated on the Element AVITI System shows a lower level of duplicates and a higher proportion of high-quality read pairs. This increases the efficiency of OncoTerra library sequencing. OncoTerra delivers genome-wide cytogenomic insights from a wide array of sample types, including blood, fresh, and frozen tissues. Phase Genomics’ OncoTerra platform is the first offering to deliver the value of scalable cytogenomics for solid-tumor malignancies in the research setting.

“Our work with Phase Genomics marks Element Biosciences’ first foray into the next-generation cytogenomics space for oncology,” said Shawn Levy, PhD, CSO and SVP of Applications at Element Biosciences. “Our collaborative work with Phase Genomics underscores the versatility of the AVITI System in accurate genomic characterization of clinically relevant samples. Phase Genomics’ innovative approach to cytogenomics amplifies our joint impact in oncology research today, advancing the latest technology toward the clinic.”

The OncoTerra platform leverages data from ubiquitous short-read sequencing technologies, like the Element AVITI NGS system, to identify novel and known genomic alterations. This information is key for oncology research applications. Phase Genomics and Element will share additional details and an application note at the upcoming AACR conference, April 14-19 (Phase Genomics booth #561, Element Biosciences booth #559). The application note demonstrates that with a single NGS-based assay, OncoTerra surpasses the breadth and depth of insights from current front-line cytogenetic diagnostics, including karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarrays.

About Phase Genomics

Phase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. In addition to a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, they also offer an industry-leading genome and metagenome assembly and analysis software.

Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

About Element Biosciences, Inc.

Media Contact

Eric Schudiske

Phase Genomics

eric@s2spr.com

Kristi Heim

Element Biosciences

Kristi.Heim@elembio.com

Element Chief Scientific Officer Shawn Levy will speak at the Revolutionizing Next Generation Sequencing Conference March 28

2023-03-24T09:52:00-07:00

SAN DIEGO, CA (March 24, 2023) – Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — announced that Shawn Levy, Element CSO and SVP of Applications, will give a keynote presentation at the Revolutionizing Next Generation Sequencing Conference taking place March 27-28 in Ghent, Belgium.

A year after launching the AVITI System, Element has continued to innovate on its modular platform, including faster run times, expanded kit offerings, the Elembio Cloud software platform, and industry-leading low costs, all while maintaining unprecedented accuracy. Shawn Levy will address these and other topics in his presentation “Avidity Sequencing on the AVITI System - Sequencing Reimagined” on March 28.

A world-renowned pioneer in genomics research, Dr. Levy has over 20 years of experience in genomic applications development and technology optimization, along with operational management of research, development, and clinical testing programs.

“Element brings new innovations to the market to revolutionize sequencing and enable more discovery,” he said. “We are proud to empower scientists around the world with higher data quality and lower costs so they can reach the next breakthroughs.”

With the establishment of a European entity and a growing sales and support organization, Element can now support a wide variety of applications and research labs. “AVITI’s flexibility, data quality, ease of use, and excellent support team are reasons why the AVITI is quickly turning into the preferred sequencer of choice for workflows that require a mid-throughput sequencer,” said Ewoud Ouwerkerk, General Manager, Europe, at Element.

About Element Biosciences, Inc.

Media Contact:

Kristi Heim

Element Biosciences

Kristi.Heim@elembio.com

Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing

2023-02-08T09:41:00-08:00

Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element’s AVITI™ System and Bio-Rad’s SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits

SAN DIEGO, Calif. and HERCULES, Calif., — February 8, 2023 — Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.

The Element AVITI Sequencing Platform’s novel Avidity Sequencing chemistry can be easily adapted for use with the Bio-Rad SEQuoia Complete Stranded RNA Library Prep Kit and the SEQuoia Express Stranded RNA Library Prep Kit to obtain RNA sequencing accuracy and repeatability among samples and different RNA inputs.

The SEQuoia Complete Stranded RNA Library Prep Kit offers unbiased transcriptome profiling during RNA sequencing by capturing a broad range of RNA subtypes in a single workflow, whether using low or high input RNA. The SEQuoia Express Stranded RNA Library Prep Kit offers the additional benefit of a highly efficient 3-tube workflow for detection of long RNAs that can be completed in only 3 hours.

The Element AVITI System, a benchtop sequencer with excellent performance, cost savings, and flexibility, combines a simple workflow with exceptional data quality. For enhanced experiment design freedom, the AVITI System features two flow cells, each operating independently, while maintaining the option to deliver up to 2 billion reads of combined sequencing output.

Recent collaborative studies show high compatibility and performance for RNA sequencing using SEQuoia library preparation chemistries on the Element AVITI System. Bio-Rad will present the results of this collaboration at the Advances in Genome Biology and Technology (AGBT) General Meeting in Hollywood, Florida, on Thursday, February 9, at 8:00 AM in Presidential Suite 3131 of the Diplomat Resort Hotel.

“The seamless integration of Element’s sequencing technology with Bio-Rad's SEQuoia portfolio helps enable cost-effective, flexible, and high-quality sequencing data for our customers,” said Shawn Levy, Chief Scientific Officer and Senior Vice President of Applications, Element Biosciences.

“We are excited to work with Element to provide RNA library preparation chemistries offering high performance for a range of sample types. The collaboration with Element will ensure that our customers can now access this new sequencing platform in a ready-to-use format,” said Steven Blakely, Senior Director for the Gene Expression Business, Bio-Rad.

Please visit bio-rad.com/NGSAGBT2023 to learn more about the SEQuoia RNA-Seq Library Preparation Kits.

BIO-RAD and SEQuoia are trademarks of Bio-Rad Laboratories in certain jurisdictions. All trademarks used herein are the property of their respective owners.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,200 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.

About Element Biosciences, Inc.

Bio-Rad Forward Looking Statements:

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Element Media Contact:

Kristi Heim

Element Biosciences

Kristi.Heim@elembio.com

Bio-Rad Media Contacts:

Bio-Rad Laboratories, Inc.

Katrina Academia, Inbound Marketing Manager

+1 510-356-7909

Katrina_academia@bio-rad.com

Zyme Communications
Esmé Walters

+44 (0) 7737 543244

esme.walters@zymecommunications.com

Tecan Collaborates with Element Biosciences to Provide Benchtop NGS

2023-02-07T09:34:00-08:00

Tecan and Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — are collaborating to offer a true benchtop NGS workflow with MagicPrep™ NGS* and the AVITI™ System. The collaboration will bring together Tecan’s automation expertise and Element Biosciences’ unique sequencing technologies, employing proprietary chemistries from both companies to deliver a hands-free NGS solution offering unprecedented performance and flexibility for a benchtop set-up.

MagicPrep NGS draws on Tecan’s many years of experience in robust liquid handling and NGS to deliver plug and play, walkway preparation of NGS libraries. This innovative solution fits perfectly with Element Biosciences’ AVITI benchtop sequencer, and the collaboration will allow direct conversion of libraries on the MagicPrep NGS – without amplification and with no reduction in quality1 – using the Adept™ Library Compatibility Kit v1.1.

Klaus Lun, Executive Vice President and Head of the Life Sciences Division at Tecan, said: “We are excited to be working with Element Biosciences, using our complementary expertise to bring automated library preparation to even more researchers. This partnership will allow customers from both our companies to take advantage of hands-free library preparation with the MagicPrep NGS system and reap the benefits it offers for low throughput applications.”

Matthew Kellinger, PhD, Vice President of Biochemistry and Co-Founder, Element Biosciences, added: “The Element AVITI System generates high quality data across all sequencing metrics when combined the Tecan MagicPrep NGS Automated Library Preparation System. This provides a powerful combination of automated convenience with AVITI’s industry-leading performance and operating cost.”

A poster on “MagicPrepTM NGS Automated Library Preparation for Sequencing on the Element AVITI™ System” will be presented at the Advances in Genome Biology and Technology (AGBT) annual meeting Feb. 6-9, 2023.

To learn more about Tecan’s MagicPrep NGS system, visit www.tecan.com/magic

1.Matt Kellinger, Ben Krajacich, Vivian Den, Andrew Altomare, Dat Mai, Thomas Sandell, Justin Lin, Ashesh Saraiya. MagicPrep™ NGS Automated Library Preparation for Sequencing on the Element AVITI™ System

* For Research Use Only. Not for diagnostic procedures.

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2021, Tecan generated sales of CHF 947 million (USD 1,041 million; EUR 877 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group

Benjamin Peltier

Senior Manager Media and Content

benjamin.peltier@tecan.com

Tel. +41 (0) 44 922 88 88

www.tecan.com

About Element Biosciences, Inc.

Media Contact:

Kristi Heim

Element Biosciences

Kristi.Heim@elembio.com

Element to Present Data and Innovation Roadmap at AGBT

2023-02-06T05:00:00-08:00

Element’s AVITI™ offers the most compelling combination of speed, accuracy, and value on the market

SAN DIEGO, CA (February 6, 2023) – Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — will present details about its new Avidity Cloudbreak™ technology and the company’s innovation roadmap at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 6-9, 2023, in Hollywood, FL.

With its new Cloudbreak chemistry coming in April, Element is accelerating the power of sequencing with 20 percent faster runs and a simplified workflow with Elevate linear libraries, all with superior accuracy at the industry's lowest cost. Element provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase.

Speed: Less than a year after its launch, AVITI is now the fastest desktop sequencer, based on average Q30+ gigabase per day. The new chemistry reduces sequencing time for 300G per flow cell down to 38 hours, 10 hours less than previously. Cloudbreak’s faster run times make it easier for researchers to maximize the output of the AVITI sequencer during daily work schedules, as one run on a 150-cycle kit can be completed every 24 hours.
Flexibility: Increasing flexibility and ease of use, Cloudbreak introduces improved workflow to reduce hands-on time.

Quality: Element has also improved overall accuracy -- with greater than 90 percent Q30, AVITI is the highest quality benchtop sequencer on the market. Element will present customer data on exome sequencing reporting the majority of bases on AVITI are >Q42, the first commercial platform consistently delivering data quality in excess of Q40.

Supporting the AVITI System, Element will also introduce the Elembio Cloud Platform (ECP), a customer-facing software portal that will allow customers to configure and manage their instruments, manage user access, and remotely monitor their sequencing runs.

“Our announcements at ABGT show Element’s commitment to rapidly delivering further improvements to the industry-leading performance researchers can achieve with AVITI,” said Matthew Kellinger, PhD, Element Vice President of Biochemistry and Co-Founder. “Our new Cloudbreak chemistry provides a foundation for our 2x300 chemistry being released later in 2023 to bring more innovative solutions to the genomics community.”

Join Element for a series of talks at AGBT, including:

Tuesday, Feb. 7, 8:00 a.m. in Lounge 212:

Carrie Cibulskis, Director, Cancer Genomics, Broad Institute Genomics Platform, will present “Evaluation of Element AVITI in Cancer NGS Assays.”

Jon Armstrong, VP of Research & Development, Jumpcode Genomics, will present “Boost your single cell studies with CRISPRclean and AVITI: Sequence less and see more usable data.”

Semyon Kruglyak, PhD, Element VP of Informatics, will present “Avidity Sequencing: Quality and Applications.”

Wednesday, Feb. 8:

Francisco Garcia, PhD, Element SVP of Software and Informatics, will present “ELEVATING Sequencing and Genomic Analysis with AVITI: Introducing AVITI OS 2.0 and Elembio Cloud,” at 8:00 a.m. in Lounge 212, followed by an Open House and Q&A with Element CTO, SVP of R&D and Co-Founder Michael Previte and scientific leadership.

Matthew Kellinger, PhD, Element VP of Biochemistry and Co-Founder, will present data on Element’s technology and future outlook in an AGBT Bronze Workshop talk, "Cloudbreak and Beyond: A Roadmap for Innovation” at 2:40 p.m. in the Grand Ballroom.

Shawn Levy, PhD, Element Chief Scientific Officer and SVP of Applications, will present a Technology/Biology session on “Avidity-based sequencing improves sensitivity and detection in metagenomic analysis” at 8:30 p.m. at the Great Hall 4-6.

The full schedule of Element events at AGBT can be found here: https://www.elementbiosciences...

About Element Biosciences, Inc.

Media Contact:

Kristi Heim

Element Biosciences

Kristi.Heim@elembio.com

Shawn Levy Elevated to Chief Scientific Officer and Senior Vice President of Applications

2023-01-26T04:00:00-08:00

SAN DIEGO, CA (January 26, 2023) – Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — announced the promotion of Shawn Levy, PhD, to Chief Scientific Officer and Senior Vice President of Applications.

A world-renowned pioneer in genomics research, Shawn has over 20 years of experience in genomic applications development and technology optimization, along with operational management of research, development, and clinical testing programs. He joined Element in February 2022 as SVP of Applications & Scientific Affairs. Under his leadership, Shawn has led Element’s applications strategy to encompass a robust set of applications on the AVITI™ platform and demonstrate its capabilities with the highest scientific standards of excellence. In his new role, he will serve as a bridge between Element’s R&D and growing Commercial operations. Michael Previte, Chief Technology Officer, SVP of R&D, and co-founder, will continue to drive the research and product development team while Shawn will focus on applications, assist with product strategy, and connect Commercial and R&D efforts.

Prior to joining Element, Shawn spent over 20 years in academia where he developed and led a number of core facilities and genome centers while a faculty member at Vanderbilt University and HudsonAlpha Institute for Biotechnology. Shawn’s research focused on technology development to support rare, inherited disease as well as pediatric and adult oncology. His research was supported with continuous funding from the NIH, including prestigious projects such as the Gabriella Miller Kids First Research Program and most recently the All of Us Research Program. His lab’s work and that of many collaborators is detailed in over 200 peer reviewed publications.

“We are honored to have Shawn’s leadership in this new role,” said Michael Previte. “In addition to his technical acumen as an innovative, methodical and disciplined scientist, his experience leading genomics facilities and projects brings an invaluable perspective to help us better understand and serve customers.”

“I was fortunate to start my career at the dawn of genomics and have been privileged to work with the majority of genomic technologies and sequencing platforms over the years,” said Shawn Levy. “Genomics is entering a new era and Element is at the forefront, bringing new innovations to market and enabling scientists to break scientific boundaries. I couldn’t be more excited to take on this role at Element and accelerate our mission."

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Delivers $200 Genome on AVITI™ Benchtop Sequencing System

2023-01-11T06:30:00-08:00

New throughput-based model allows customers of all sizes to benefit from flexibility and lowest cost today

SAN DIEGO, CA (January 11, 2023) – Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — announced a new throughput-based option for its AVITI System that provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase. For single cell sequencing, the new model offers potential costs as low as $0.60 per million reads, with sequencing runs finishing in less than 24 hours.

“Our goal is to enable labs everywhere to produce high-quality data at the lowest cost,” said Molly He, PhD, Element CEO and Co-Founder, speaking today at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. “Making a $200 genome available on benchtop systems today is an important milestone in that mission.”

Element’s throughput-based model allows customers of all sizes the flexibility to benefit from AVITI’s groundbreaking innovation. It is available today, subject to volume purchase requirements and other terms and conditions. Customers with existing high throughput can take advantage of volume-based prices to bring costs even lower. Customers who anticipate future growth can buy only the instrumentation they need now, while establishing a stepwise path to $200 genomes as they expand over time, without the need for disruptive equipment changes.

“We are excited to work with Element Biosciences to provide additional value to our genomics sequencing customers in the agriculture market,” said Dr. Jason Lilly, VP International Business, Neogen Corporation. “The model announced today allows Neogen laboratories around the globe to offer excellent genomics services closer to our customers, at a faster turnaround time, without the need for batching or consolidating samples at one central location, thereby enhancing our global service model. The Element Biosciences AVITI is redefining the capabilities of a benchtop sequencer.”

“AVITI was built to lead a movement to increase the access of high-quality sequencing and offer the freedom of genomics science studies without waiting to batch samples,” said Michael Previte, PhD, Element Chief Technology Officer, SVP of R&D and Co-Founder. “While we are only at the beginning of our innovation cycle, AVITI is the only ubiquitous sequencing solution on the market today that delivers the unrivaled combination of cost, quality, turnaround time and long-read solutions.”

For details about the program, please contact an Element sales representative here: https://www.elementbiosciences.com/200-dollar-genome

About Element Biosciences, Inc.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Michael Galfetti
Mission North
elementbiosciences@missionnorth.com

Element CEO and Co-Founder Molly He to Speak at 41st Annual J.P. Morgan Healthcare Conference

2023-01-04T04:00:00-08:00

SAN DIEGO, CA (January 4, 2023) – Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — announced that Element CEO and Co-Founder Molly He will speak at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) at the Westin St. Francis hotel in San Francisco.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating the fundamental elements of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, in turn accelerating scientific discoveries and broadening the use of genomic medicine. To learn more about Element, visit www.elementbiosciences.com.

Media Contact:
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

Element Drives Industry Innovation with New Avidite Cloudbreak™ Technology and a 2x300 Kit

2022-12-07T04:00:00-08:00

Faster Run Times and More Applications in 2023

SAN DIEGO, CA (Dec. 7, 2022) – Element Biosciences, Inc.—developer of an innovative DNA sequencing platform that is disrupting the genomics industry—today announced avidite Cloudbreak technology: improvements to chemistry kits for the current Element AVITI™ System that reduce run times and enable even more applications.

Available in early 2023, avidite Cloudbreak includes innovations to:

Reduce run times to fewer than 40 hours for a 300-cycle kit and fewer than 24 hours for a 150-cycle kit, including amplification time and onboard demultiplexing.
Enable linear library loading for Elevate™ libraries through onboard circularization, which simplifies the workflow and reduces hands-on time.
In addition to standard configurations, an AVITI System with Cloudbreak can be configured to achieve 1B+ reads (dual-sided) in less than 20 hours for an indexed 2x75 run, or less than 30 hours for an indexed 2x150 run.
Avidite Cloudbreak will, of course, maintain the AVITI System's core competitive advantages, including market-leading data quality with a diversity of read lengths, at a stable reagent cost of less than $6 per gigabase.

Less than one year after launching the AVITI System, Element continues to rapidly advance its technology and expand product offerings. Avidite Cloudbreak will further enable Element to release a 2 x 300 sequencing kit, earmarked for 2023. With yields of 1.6B reads (dual-sided) at a 2 x 300 read length, Cloudbreak will set a new benchmark for cost-effective sequencing at extended read lengths that advance applications such as de novo assembly of small genomes, immune repertoire sequencing, and isoform discovery.

“Development of the Cloudbreak chemistry demonstrates Element’s constant commitment to push the envelope on our technology. In less than a year since the launch of AVITI, this chemistry will reduce runtimes by almost 20% and simplify customer workflows while delivering exceptional data quality and throughput in the benchtop space. Element continues to set new standards in short read sequencing and Cloudbreak chemistry will pave the way for even more versatile 2x300 configurations later in 2023,” said Matthew Kellinger, Element Vice President of Biochemistry and co-founder.

“We are excited to see the new capabilities of the AVITI technology. Our company is investigating novel liquid biopsy biomarkers for critical disease areas that have unmet diagnostic needs, and faster times and increased accuracy would make a significant difference in our research,” said Dr. Chris Booth, CEO of FYR Diagnostics. “Element is redefining what is possible to do on a benchtop sequencer.”

“Our team at Element is driving genomics forward with the mission to empower labs everywhere with access to the highest quality genomics at the lowest cost,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “We continue to advance our technology at lightning pace to enable health innovation because science can’t wait.”

About the Element AVITI System

The AVITI System operates two random access flow cells for independent run starts, with AVITI Operating Software that features tunable read throughput for additional flexibility. Proprietary avidite sequencing chemistry enables exceptional accuracy and cost efficiency that remains unmatched by other benchtop systems. To learn more about the AVITI System, including detailed specifications, application data, and performance testimonials, visit www.elementbiosciences.com.

About Element Biosciences, Inc.

Media Contact:
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

206-778-7411

Element Introduces New Element LoopSeq™ Long-Read Sequencing Kits Designed for the AVITI™ System

2022-11-10T04:00:00-08:00

Affordable, On Demand Access to High-Quality Long Reads on a Benchtop Sequencer

SAN DIEGO, CA (Nov. 10, 2022) – Element Biosciences, Inc.— developer of an innovative DNA sequencing platform disrupting the genomics industry — today announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument. Element is the first company to own a general purpose long-read technology that runs on its native short-read sequencer.

Element LoopSeq is an extraordinary long-read sequencing chemistry that provides synthetic long-read capabilities on AVITI. Element LoopSeq provides highly accurate continuous long reads, a data type identical to the output of legacy long-read technologies but without the need for an additional dedicated instrument.

“The release of the Element LoopSeq kits introduces general-purpose, highly accurate long-read capabilities to AVITI at a price per base pair that would otherwise only be available on much bigger and more expensive sequencers,” said Tuval Ben-Yehezkel, PhD, Senior Director, Applications.

Element LoopSeq, which offers read lengths up to 5 kilobases, enables many sequencing applications where longer reads can improve understanding of biological systems, such as the diversity of bacterial communities, novel mRNA isoforms, oncogenic fusion genes, the immune repertoire, the evolution of mutant and recombinant viral genomes, and the engineering of proteins, to name a few.

As one example, Element’s LoopSeq™ proved to be a vital tool for wastewater-based surveillance of the spread of enteroviruses during the COVID-19 pandemic, said Temitope Faleye, PhD, at the Biodesign Center for Environmental Health Engineering, Arizona State University. “Using LoopSeq we developed and tested a novel method for long-read sequencing for WBE, which provides critical information on how the viruses move through communities that cannot be accessed with short reads," Faleye said.

“Thanks to the outstanding collective effort following our acquisition of Loop Genomics, we are able to roll out a groundbreaking new product kit at Element today,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “This demonstrates the pace of our continued innovation and drive to democratize access to long-read and all types of sequencing for the benefit of science.”

Orders are being taken for the Element LoopSeq kit now, and shipments will start in early December. The new Element LoopSeq Kits come in two configurations, both including all the reagents required to make a sequencing read library:

Amplicon LoopSeq for AVITI is a general-purpose kit for sequencing any amplicon or long double stranded DNA of choice. It supports up to 96 samples with a multiplexed workflow.
For microbiome researchers, 16S LoopSeq for AVITI enables full-length 16S sequencing for up to 96 samples on the AVITI system.

Element will host a webinar Nov. 15 on using LoopSeq long-read wastewater surveillance to understand Enterovirus epidemiology. Register here: https://www.elementbiosciences.com/events/webinar-beyond-covid

For more information about Element LoopSeq, other LoopSeq kits and the AVITI System, including detailed specifications, application data, and performance testimonials, visit www.elementbiosciences.com

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every aspect of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, to accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com.

Media Contact:

Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com

(206) 778-7411
elementbiosciences@missionnorth.com

Element Biosciences Delivers 1B Reads and Provides Industry’s Lowest Cost for Single-Cell Sequencing

2022-09-27T02:45:00-07:00

Element Biosciences, Inc. - developer of an innovative DNA sequencing platform set to disrupt the genomics industry - today announced updated specifications to their AVITI™ System, increasing the platform's specifications from 800 million reads per flow cell to 1.0 billion reads per flow cell*, further reducing the price per Gigabase (or run).

“We launched with a conservative specification of 800 million reads passing filter, but after thousands of additional runs (both internal and external) we have determined that we can comfortably go beyond 1.0 billion reads and maintain our leading data quality,” explained Francisco Garcia, Senior Vice President of Informatics at Element Biosciences.

Element is also launching the AVITI 150-cycle sequencing kit at the end of October for researchers who want to do short-read sequencing such as bulk RNA-seq, single-cell RNA-seq, single or paired-end short-read length sequencing. This will be available to all customers at a price of $1,080 per kit, delivering the lowest costs in the industry at less than $1.00 per million reads. AVITI’s affordability and flexibility obviates the need for batching samples, which is the main source of delays to receiving results.

“Element Biosciences was founded to enable scientists to do more with their resources. We have come a long way but sequencing is still too expensive. The AVITI is bringing us into a new era of sequencing – one where labs of all sizes and budgets can produce their own high quality data,” said co-founder and CEO Molly He.

Many labs across the country support a growing number of single-cell projects and want to find a way to do them cheaper and faster. Dr. Lutz Froenicke, Core Director at UC Davis and an AVITI user, stated “The Genome Center at UC Davis supports numerous single-cell sequencing projects and single-cell protocols. Both maximizing our researchers’ dollars and improving the turnaround times are of the utmost importance. We are excited for the release of Element Biosciences 2 x 75 bp sequencing kit so that we can provide the highest quality data faster to our researchers at a price point that has never been seen before.”

The new 150-cycle sequencing kits will also fall under the Element’s reagent price guarantee for the lifetime of the AVITI System, ushering in stability and making it easier for labs to accurately forecast costs. Learn more about the AVITI System, including detailed specifications, application data, and performance testimonials.

Learn More About AVITI

*Read count based on Element control library sequencing. Actual read count may differ based on factors such as library type and preparation.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media Contact: elementbiosciences@missionnorth.com

Element Biosciences Welcomes Former ThermoFisher Executive Shelly Peariso to Growing Commercial Team

2022-09-01T09:00:00-07:00

Element Biosciences, Inc.— developer of the AVITI™ System, a new and disruptive DNA sequencing platform — today announced they are adding an industry veteran to their commercial team.

Shelly Peariso has been a life science and clinical sales executive for more than 20 years. Most recently, Shelly led the Americas Commercial Organization in the Clinical Next Generation Sequencing Division at ThermoFisher, where she was responsible for the development and execution of sales strategy for the entire Ion Torrent Next Generation Sequencing portfolio across clinical, applied, and research markets. Shelly started her sequencing career at Applied Biosystems in 2005 selling Capillary Electrophoresis and then transitioned to selling Next Generation Sequencing when SOLiD was introduced to the market.

"I haven't seen researchers this animated since Next Generation Sequencing hit the market. After years of incremental progress, Element Biosciences has brought exponential thinking back to the field," said Shelly Peariso, Vice President of Sales. "I am so excited to talk to scientists about what this level of data quality, flexibility, and price means for them and what they can achieve with an AVITI."

"Shelly was a driving force behind the first major uptick in Next Generation Gene Sequencing in the early 2000's and has worked with every aspect of the technology, from reagents to instrumentation, since then. We're so lucky to have her on the team as we continue to grow our commercial operations and define what the next generation of genomic sequencing means," said Mark Aitkenhead, Chief Commercial Officer.

Shelly earned a B.S. in Biology from Lake Superior State University while on scholarship for volleyball, and an M.S. Degree in Biomedical Chemistry from Thomas Jefferson University. In her free time, Shelly likes traveling, baking, and playing golf. She splits her time away from serving customers between New Jersey and Florida.

Announcing Reagent Price Guarantee for the Lifetime of the AVITI™ System

2022-08-09T00:05:00-07:00

Lifetime Reagent Price Guarantee Announced by Molly He, CEO & Co-Founder of Element Biosciences

Element Bucks Industry Trends by Committing to Not Increase Price of Reagents

Element has departed from industry norms by setting consistent and disruptive pricing. The current industry standard is to offer different discounts to different customers, leading some customers to pay significantly more for the same product on top of standard annual price increases. This opaque pricing is one source of frustration among the scientific community. Reagent costs are one of the main drivers of a lab’s operational budget and a key reason most customers “batch” samples. To realize the most economical price per gigabyte, labs wait to fully fill a flow cell before sequencing on existing systems. Depending on the sequencing platform used and the throughput of samples coming in, it can sometimes take several weeks to fill a flow cell. This causes inherent delays in the end-user obtaining their results.

“Our zero price increase commitment is core to our mission to enable more science to be done faster and cheaper by the global scientific community. The AVITI system delivers unprecedented data quality and flexibility, now at even better value with added assurance of lifetime affordability,” explains Molly He, PhD, CEO and co-founder of Element Biosciences.

Element Bioscience’s published price for one 300-cycle sequencing kit is $1,680 and the company will keep this price flat for the lifetime of the AVITI system. This will also apply to the 150-cycle kit, priced at $1,080, which will launch by the end of 2022. With current market volatility and inflationary pressures, the efforts announced today will allow researchers to more accurately plan and resource sequencing costs for the future.

“Having been at the bench myself, it is very valuable for a scientist or lab director to have future visibility of their reagent costs, which is a big part of their ongoing operational costs. Keeping prices flat in the highest inflation period of the past 40 years shows our deep commitment to our mission and confidence in our product and innovation roadmap. This is one of many steps Element plans to take in our laser-focused commitment to drive down the cost per genome while leading with the best data quality,” said He.

View associated Terms & Conditions here.

Element AVITI™ System

The AVITI™ System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI operating software features tunable read throughput control for additional run time flexibility. Element’s proprietary Avidity Sequencing™ chemistry enables exceptional accuracy and cost efficiency that is unmatched by other benchtop systems. Full product features, specifications, and pricing can be found here.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media Contact: elementbiosciences@missionnorth.com

Element Announces First Customer Shipments and New Offerings for AVITI™ System

2022-06-08T11:05:00-07:00

The Element AVITI™ System, a next-generation benchtop sequencer

Element Biosciences, Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced it has shipped multiple AVITI systems to its first set of customers. Additionally, Element is introducing new volume-based pricing, launching ElemBio Capital Solutions™ for financing and leasing options, and announcing the upcoming launch of its new AVITI 150-Cycle Sequencing Kit to ship Q4 2022. This is all to meet rapidly growing customer demand following the commercial launch of the AVITI System in March. The details of Element’s newest customers, offerings, and pricing were shared earlier today at the “Elements of Freedom” workshop during the 2022 AGBT General Meeting.

Shipping of AVITI Has Begun

Element has begun shipping AVITI to its first set of customers, comprised of major core labs and genome centers in the US, with some customers purchasing multiple units.

“The commitments of these leading institutions to use the AVITI System are important milestones for Element and the sequencing industry overall, representing major inflection points as we realize our vision to dramatically expand access to high quality, low-cost, and easy-to-use genomics tools,” said Molly He, PhD, CEO and co-founder of Element. “As we continue to expand our customer base with strategic early adopters, we are also continuing to grow our partner footprint with industry-leading institutions in the next generation sequencing space to ensure that AVITI works in any research environment as a ‘plug-and-play’ system in support of our mission of accessibility and democratization.”

New AVITI System Offerings and Incentives

The AVITI System is based on a single flow cell and sequencing reagent cartridge design that offers up to 300 cycles and tunable read throughput control for each of two independently operated flow cells. Today, Element announces its upcoming launch of the AVITI 150-Cycle Sequencing Kit, designed for researchers who want to do short-read sequencing such as bulk RNA-seq, single-cell RNA-seq, single or paired-end short-read length sequencing. This offering will be available to all customers in Q4 2022 at a price of $1080 per kit, delivering unprecedented $1-1.35 per million reads at >90% Q30 on a desktop instrument in each lab that doesn’t require batching, a truly unique offering in the sequencing market.

For customers who want multiple units, Element will now offer special bundled pricing for customers who purchase three or more units. The bundled price will be $249,000 for each instrument, as compared to the current standard pricing of $289,000 per unit if purchased individually. In addition, Element is launching ElemBio Capital Solutions™ in partnership with DLL, a global financial solutions provider and fully-owned subsidiary of the Rabobank Group, which will provide financing and leasing options for customers who want to get started quickly without upfront ownership costs.

“Consistent with our unrelenting focus on advancing scientific discoveries and our desire to democratize sequencing, we continue to bring forward features and options that will ensure the accessibility of high quality, affordable sequencing to all researchers,” said Shawn Levy, PhD, Senior Vice President of Applications and Scientific Affairs at Element. “Demand for the AVITI System has been very robust and our latest offerings reflect our commitment to remaining adaptive to meet the varied needs of the research and diagnostic markets we serve.”

Element at AGBT

As a Silver Sponsor of the 2022 AGBT General Meeting, the Element team is on-site at the event in full force, with several presentations and events to highlight the benefits of the AVITI System. Today, Element presented its “Elements of Freedom” workshop in a panel moderated by Element’s Shawn Levy and joined by industry leaders who shared their firsthand experiences with the AVITI System and its potential to be a disruptive game-changer in genetic sequencing. The panel will feature Andrew Carroll from Google DeepVariant, Chris Mason from Weill Cornell, Sheila Dodge from the Broad Institute, and Michael Previte, PhD, Element’s co-founder, Chief Technology Officer, and Senior Vice President of R&D.

Element continues to expand its bench of key partnerships with established and emerging leaders in the NGS Library Prep and Bioinformatics segments, each of whom demonstrate powerful use cases for the AVITI System. In addition to its previously announced partners, Element has added Olink, Miroculus, Gencove Inc., Volta Labs, and seqWell.

Element AVITI System

The AVITI System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI operating software features tunable read throughput control for additional run time flexibility. Element’s proprietary avidity sequencing chemistry enables exceptional accuracy and cost efficiency that is unmatched by other benchtop systems. Full product features, specifications, and pricing can be found here.

Learn About AVITI

Element and Olink Collaborate to Enable Olink® Explore on the Element AVITI™ System

2022-06-07T05:02:00-07:00

Element Biosciences to provide proof-of-concept findings during panel discussion at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting.

Olink continues its pioneering efforts to enable Explore broadly across genomics ecosystems and to democratize next-generation proteomics.

Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) and Element Biosciences, Inc. (“Element”) today announced a collaboration to enable use of the Olink® Explore high-throughput proteomics platform with Element’s next-generation sequencing (NGS) platform, the Element AVITI™ System, launched March 2022.

Element and Olink have performed a technical proof-of-concept study demonstrating a high compatibility between Olink® Explore and Element’s NGS platform AVITI. Additional findings from the two companies’ results will be discussed by Element during a panel discussion on June 8^th at the AGBT general meeting in Orlando, Florida. Element and Olink are exploring more advanced means of seamlessly combining the existing Olink® Explore product with Element’s AVITI System in additional use cases.

“Olink is dedicated to driving the understanding of real-time biology and making our Olink® Explore line of products broadly accessible to labs across the world,” said Jon Heimer, CEO of Olink. “With new product launches such as AVITI helping drive continued expansion and evolution of the NGS market, Olink looks forward to its efforts with Element to bring Explore to an increasing number of customers."

“Olink’s Explore technology is a great example of how the AVITI System benchtop sequencer—with its flexible sequencing configurations and high data quality—can have an impact beyond DNA sequencing by providing users high performance and low cost access to other areas of investigation,” said Shawn Levy, SVP of Applications and Scientific Affairs, Element Biosciences.

This non-exclusive collaborative framework is a continuation of Olink’s strategy it has executed in NGS since 2020 and combines the strengths of both companies’ technologies. These efforts are intended to provide Olink customers with options in choosing the sequencing platform that is optimal for their needs, and to expand the portfolio of applications for Element Biosciences customers.

About Olink

Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
Learn more about Olink here.
Investor contact for Olink Proteomics AB: Jan Medina, CFA - VP Investor Relations & Capital Markets | jan.medina@olink.com | (617) 802-4157
Media contact for Olink Proteomics AB: Andrea Prander - Corporate Communications Manager | andrea.prander@olink.com | +46 768 775 275

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine.
Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Olink use of forward-looking statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our 2022 revenue outlook, our Explore externalizations, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the caption "Risk Factors" in our Form 20-F (Commission file number 001-40277) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections for the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Element Debuts New Headquarters in San Diego

2022-05-26T04:50:00-07:00

Molly He cuts the ribbon at the opening ceremony of Element Biosciences' new headquarters in Sorrento Valley. Pictured (left to right): Dan Ryan, San Diego Mayor Todd Gloria, Molly He, Michael Previte, Matthew Kellinger, Joe Panetta, Logan Zinser.

Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive benchtop DNA sequencing platform, today announced that it has moved its headquarters to the Alexandria Tech Center located on the 37-acre, 14-building campus in the Sorrento Mesa life science hub of San Diego, California. Alexandria Tech Center includes amenities such as a fitness center, fire pits, meditation gardens, eateries, and conference space. Element will anchor 10055 Barnes Canyon Road, occupying 186,000 square feet. The five-story building is designed for a 50/50 mix of lab and general office space featuring an open concept with natural materials like wood and concrete.

Element celebrated this debut event at its official ribbon-cutting ceremony yesterday, with remarks from its CEO and co-founder, Molly He, PhD, and SVP of Finance and Administration, Logan Zinser, CPA. Special guests included City of San Diego Mayor, Todd Gloria, President and CEO of Biocom California, Joe Panetta, and co-chief investment officer and San Diego regional market director of Alexandria Real Estate Equities, Inc., Daniel Ryan.

“We are excited to move into our new headquarters as we continue to grow and disrupt every ‘element’ of the DNA and genetic sequencing market with AVITI,” said Dr. He. “Our technology will empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity — so that together, we can realize the incredible.”

Since its inception in 2017, Element has assembled a team of experts in various fields, including biologists, geneticists, scientists, and engineers with experience developing genetic tools. With the launch of AVITI and other technologies in the pipeline, the company continues to expand its workforce in several key areas including commercial, finance and accounting, and general and administrative services. This move will consolidate employees working in three separate locations under one roof and provide the additional space needed for future workforce growth. The Alexandria Tech Center campus is designed to promote health, wellness, and productivity so that employees can “work the way they live” while giving employers an edge to attract and retain the most talented individuals.

Element is a vital part of San Diego’s life sciences community, which is considered the third-largest biotech and pharmaceutical hub in the nation. In 2020, San Diego County's life science industry directly employed more than 72,000 people and was responsible for nearly 178,000 jobs with total earnings of $16 billion, according to Biocom California’s 2021 Economic Impact Report.

“With AVITI, Element is eliminating the barriers to research access and expanding the opportunities for research innovation — by creating more affordable, adaptable, and accurate life science tools for basic, applied, and clinical research,” said Dr. He. “This technology enables researchers to better understand biology and improve human life — from decoding the basis for infectious diseases like COVID-19, to determining the genetic profile of individual cancers and inherited diseases, to discovering and developing new drug therapies.”

Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Appoints Mark Aitkenhead, PhD, as Chief Commercial Officer

2022-05-23T04:50:00-07:00

Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced the appointment of Mark Aitkenhead, PhD, as Chief Commercial Officer. In this role, Dr. Aitkenhead will build, guide, and manage the customer-facing functions of the company, including sales, marketing, customer support, and training. As a member of the executive leadership team, he will also develop and implement strategies for driving adoption of current and future products in the marketplace.

“The depth and breadth of Dr. Aitkenhead’s commercial expertise is impressive, and we are excited to have him join our leadership team,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “Throughout his career, he has demonstrated that he can develop and lead high-growth, high-performing commercial teams, and under his leadership, Element will continue to bring transformative solutions to the market that will empower more scientists and accelerate genomic discoveries.”

Prior to joining Element, Dr. Aitkenhead worked in a variety of leadership positions at Thermo Fisher Scientific since 2003, including most recently, General Manager for Cellular Analysis Instrumentation and Global Commercial Leader for the Clinical Next Generation Sequencing (NGS) Division. In the latter, he was accountable for the sales strategy and execution of the entire Ion Torrent NGS portfolio, a leading provider of clinical NGS instrumentation, assays, and consumables in oncology, applied, and research labs. During his tenure at Thermo Fisher, Dr. Aitkenhead also worked in technical and application support, field sales, and global customer care strategy. He received both his PhD in Anatomy and BMedSci in Biomedical Sciences from The Queen’s University of Belfast in Northern Ireland.

“I look forward to working with the team at Element to democratize access to genomics for the research and diagnostic markets with the recent launch of the AVITI™ System, a benchtop sequencer that offers an unrivaled combination of performance, cost, and flexibility,” said Dr. Aitkenhead. “I am honored to be a part of a company that is disrupting next-generation sequencing so researchers can expand the boundaries of science and have it all.”

Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Expands Leadership Team to Grow Commercial Presence in the DNA Sequencing Market

2022-05-09T08:40:00-07:00

Kelly Choi, MD, Joins as Senior Vice President, Marketing and Product Management

Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced the appointment of Kelly Choi, MD, as Senior Vice President, Marketing and Product Management. Dr. Choi brings 20 years of commercial leadership experience in product strategy and execution, strategic partnerships, business development, client relations, and operations management for healthcare technology companies.

“With her impressive background, Dr. Choi will amplify our commercialization efforts and market our newly launched AVITI System to ensure that we successfully deliver on our promise of empowering the scientific community with more freedom to study biology,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “We continue to assemble an outstanding executive leadership team at Element so that we can make genetic analysis more accessible and adaptable to a broad customer base.”

In her new role, Dr. Choi will build, guide and manage product strategy, strategic marketing, field marketing and product management. She will work closely with the leadership team and Board to develop external partnerships and implement strategies for appropriately positioning and driving adoption of current and future products in the marketplace.

Prior to joining Element, Dr. Choi was Chief Commercial Officer at Onegevity, a start-up within the science-driven wellness company, Thorne HealthTech, where she was responsible for building and growing their B2B business and scientific partnerships. She gained significant experience in the precision oncology space working with cancer providers, researchers and life science companies during her time at Tempus Labs, GenomOncology and COTA (Cancer Outcomes Tracking Analysis). Earlier experiences include brand marketing at Novartis and management consulting at McKinsey & Company.

Dr. Choi completed her fellowship in cardiology at Duke University School of Medicine in North Carolina after finishing her residency in Internal Medicine at Northwestern Medical Center and medical school at the Feinberg School of Medicine at Northwestern University in Chicago.

“I am excited to join Element and support the efforts of both the commercial and R&D teams to democratize access to genomics by developing the right technologies into critical products,” said Dr. Choi. “With the AVITI System, customers in the research and clinical markets now have the tools they need to accelerate scientific discoveries and broaden the use of genomic medicine overall.”

Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Launches the AVITI™ System to Democratize Access to Genomics

2022-03-14T09:00:00-07:00

Introducing AVITI™ - a benchtop DNA sequencer with unprecedented performance, cost, and flexibility.

Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, today announced the commercial launch of the Element AVITI™ System, a benchtop sequencer offering an unrivaled combination of performance, cost, and flexibility. Element’s proprietary avidity sequencing chemistries enable exceptional accuracy and cost efficiency that is unmatched by other benchtop systems. The AVITI™ System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI™ operating software features tunable read throughput control for additional run time flexibility.

The launch of the AVITI™ System is the latest in a series of announcements that have highlighted Element’s key partnerships with established and emerging leaders in the NGS Library Prep and Bioinformatics segments, each of whom demonstrates powerful use cases for the AVITI™ System.

These partners include, in alphabetical order:

“With the launch of our AVITI™ System, Element is delivering on its vision to dramatically expand access to high quality, low cost, easy-to-use genomics tools,” said Molly He, Ph.D., CEO and co-founder of Element Biosciences. “And with the recent Loop Genomics acquisition, we will offer both short and long-read capabilities on a single platform. AVITI™ will bring the ultimate freedom and flexibility for users.”

“In beta testing both the library compatibility and sequencing performance proved to be as straightforward and impressive as we’d hoped. Users will feel very confident with adopting the AVITI™ System in terms of both workflow and data quality,” said Shawn Levy, Senior Vice resident of Applications and Scientific Affairs, Element Biosciences.

“There is often a sacrifice between accuracy, throughput, and costs. With Element’s new benchtop sequencer, researchers will not be forced to make those compromises. They will receive industry-leading quality and cost at a throughput level that more closely matches the needs of most applications,” said John Stuelpnagel, chairman of Element Biosciences.

Element has released seven application and technology notes along with five sequencing datasets for download that cover human whole genome, bacterial whole genome, and RNA-Seq assays using the Element AVITI™ System.

Element is now accepting orders for the AVITI™ System, with shipments expected to begin in Q2 2022.

The Element AVITI™ System

The AVITI™ System consists of a benchtop NGS instrument and associated consumables that feature:

Proprietary Chemistries: Delivers exceptional sequencing accuracy while dramatically lowering operating costs and eliminating index misassignments due to amplification
State of the Art Performance: Accuracy and output metrics that enable a comprehensive range of demanding NGS applications
Random Access Dual Flow Cells: Scalable output and batch control features; equivalent to having two sequencing systems in one
Simple NGS Library Prep Compatibility: Easy PCR-free workflow that allows you to start immediately with your library prep of choice
Open Informatics: FASTQ file output without proprietary requirements for analysis

Key Operating Specifications

The Element AVITI™ System is based on a single flow cell and sequencing reagent cartridge design that offers up to 300-cycles and tunable read throughput control for each of two independently operated flow cells. This allows the user complete run control timing and scalability while being unburdened from the order and inventory complexity of multiple kit sizes.

The AVITI™ System’s operating specifications include:

2 x 150 paired end read length
> 90% Q30 at 2x150 read length
800M+ paired end reads per flow cell
240Gb of data output per flow cell
2 random access flow cells for 480Gb combined output
13-48 hour run time
$5-$7 per Gb run cost*
AVITI™ Instrument Pricing: $289,000

*Range determined by flow cell output, which can exceed 1000M paired-end reads per run

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with Interpretation Expert Genoox to Validate the AVITI™ System for the RUGD Application

2022-03-01T04:50:00-08:00

Element Biosciences partners with interpretation expert Genoox to validate the AVITI™ System for the RUGD Application

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Genoox, a community-driven genomic data platform, to demonstrate the clinical potential of the AVITI™ system for rare and undiagnosed disease research, using whole-genome sequencing.

An initial study, in collaboration with Dr. Radha Ayyagari, Professor of Ophthalmology and Pathology at the Shiley Eye Institute, UC San Diego, utilized the AVITI™ platform to sequence DNA from 10 individuals with a rare eye disease. In 5 of the cases, high confidence candidate variants were identified by the interpretation platform Franklin, developed by Genoox. Pending clinical validation, the anticipated diagnostic yield of the study is 50%.

The use of sequencing data in clinical research has grown at a staggering pace. The density of data in genome-wide approaches has resulted in an interpretation bottleneck. The tools developed by Genoox and its unique community greatly speed the interpretation process by rapidly identifying a small set of variants most likely to cause the phenotype of the patients.

“We are pleased to partner with Genoox,” said Molly He, Ph.D., CEO, and co-founder of Element. “Our initial study demonstrated how effectively the joint offering works for whole genome sequencing and variant interpretation.”

“The accuracy of the sequencing data that is being produced by Element Biosciences and its AVITI system has the power to unlock the value of whole-genome sequencing and create lasting impacts for the genomics industry,” said Amir Trabelsi, Ph.D., CEO, and co-founder of Genoox. “Combining the technologies of Element and Genoox enables actionable insights to be drawn from that data.”

To learn more about the AVITI System, including detailed specifications, application data, and performance testimonials, register now for Element’s virtual event on March 14, 9am PT / 5 pm CET, using the link below:

About Genoox

Genoox harnesses the power of its community to enable actionable insights from the most diverse genomic database supporting geneticists and expert physicians at the point of care. Genoox's cloud-based AI platform, Franklin, connects clinicians, genetic counselors and healthcare organizations, while enabling platform users to make impactful discoveries using the most advanced genomic tools and applications. Genoox is used by over 1,700 health organizations, hospitals, and medical facilities in 44 markets across the globe. Visit our website for more information at: www.genoox.com | franklin.genoox.com.
Media contact for Genoox: Shahni Ben-Haims | pr@genoox.com | (408) 497-8568

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with Fabric Genomics to Demonstrate the AVITI™ System’s NGS Data Quality and to Explore Clinical Applications

2022-02-28T05:10:00-08:00

Element Biosciences Partners with Fabric Genomics to Demonstrate the AVITI™ System’s NGS Data Quality and to Explore Clinical Applications

Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Fabric Genomics Inc. to explore commercialization of end-to-end clinical application solutions based on Element’s AVITI™ system and the Fabric Enterprise clinical interpretation platform.

Two initial studies confirmed the ability of the AVITI™ system to identify pathogenic variants in targeted panels and whole-genome sequencing cases as well as its seamless workflow compatibility with Fabric’s clinical interpretation platform.

To support the development of AVITI-based end-to-end clinical application solutions, Fabric will leverage its clinical genomics decision-support system, recently published in the New England Journal of Medicine as part of Genomics England’s 100,000 Genomes Project on rare disease diagnosis. The platform’s reporting is backed by a world-class team of variant interpretation geneticists.

“We are pleased to partner with Fabric Genomics. Developing robust clinical sequencing end-to-end solutions will allow Element to address unmet needs of clinicians and patients around the world,” said Molly He, Ph.D., CEO, and co-founder of Element.

“We are excited to partner with Element Biosciences,” said Martin Reese, Co-Founder and CEO of Fabric Genomics. “We believe that AVITI’s data quality and seamless integration potential will allow us to develop highly accurate and scalable solutions for the clinic.”

To learn more about the AVITI™ System, including detailed specifications, application data, and performance testimonials, register now for Element’s virtual event on March 14, 9am PT / 5 pm CET, using the link below:

About Fabric Genomics

Fabric Genomics is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support, and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women’s health. Visit our website to learn more.
Media contact for Fabric Genomics: Tim Ingersoll | tim@bioscribe.com

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Becomes the Newest Member of 10x Genomics’ Compatible Partner Program (CPP) Across Multiple Single Cell Applications

2022-02-28T05:05:00-08:00

Element Biosciences Becomes the Newest Member of 10x Genomics’ Compatible Partner Program (CPP) Across Multiple Single Cell Applications

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, which demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single-cell technologies.

10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, chemistry, and software to give single-cell and spatial views of biology at a scale and efficiency that is unprecedented. The combination of the AVITI System’s performance, cost, and flexibility with 10x Genomics’ leading single-cell assays provides customers with more access and choice for their biological research.

“We are excited about the partnership we’ve established with 10x Genomics and our new status as a validated CPP member,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. “As one of the most exciting new areas in NGS, we believe this will help bring 10x Genomics’ and Element Biosciences’ customers together for our combined performance and cost advantages in single-cell and spatial analysis.”

“At 10x Genomics, part of our commitment to supporting our customers with single-cell and spatial analysis is ensuring they have access to advanced sequencing solutions through rigorous validation,” said Brad Crutchfield, Chief Commercial Officer, 10x Genomics. “We are excited to certify Element through our Compatible Partner Program and provide our customers with more ways to adopt single cell and spatial analysis to enhance their research and fuel scientific discoveries.”

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend, and have been cited in over 3,300 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 1,300 issued patents and patent applications.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with Informatics Experts Sentieon and Google DeepVariant to Validate the AVITI™ System’s NGS Data Quality for Variant Calling

2022-02-28T05:00:00-08:00

Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, today announced partnerships with both Google DeepVariant and Sentieon for variant calling analysis. Through the partnerships, the DeepVariant and Sentieon teams have evaluated Element data and generated Element-specific machine learning models. Element will continue to work with both teams to further improve quality and ease of use. Customers who purchase an Element instrument will be offered a 6-month Sentieon license to process Element data at no cost.

The rapid expansion of next-generation sequencing (NGS) data and the use of these data in a wide range of new applications has created a need for improved computational tools for data processing.

Google DeepVariant, a deep learning technology, was specifically designed to reconstruct genome sequences from NGS sequencing data with significantly greater accuracy than previous classical methods. DeepVariant accomplishes this by transforming the task of NGS variant calling into an image classification problem well-suited to Google’s existing technology and expertise. DeepVariant is available under the BSD open source license.

Sentieon, a developer of highly accurate and optimized algorithms for bioinformatics applications, has created tools that are faster and cheaper alternatives to the industry standard for secondary analysis in NGS data processing. Sentieon technology provides high accuracy and ease of use, while dramatically improving processing speed.

“We are excited about the partnerships with both Sentieon and Google DeepVariant, and the high data quality our new AVITI System has demonstrated with both of their variant calling algorithms. This will only further enhance the user experience for all our respective customers,” said Molly He, Ph.D., CEO, and co-founder of Element.

“We are delighted to support Element Biosciences’ AVITI sequencing platform as it enters the NGS market,” said Jun Ye, CEO of Sentieon. “This partnership enables Element’s customers to benefit from each of our respective strengths in NGS data generation and data analysis. It has been a pleasure working with Element to improve variant calling. Their data has consistently high quality, leading to very accurate variant calling results. We look forward to serving their customers and continuing our collaborations.”

“We are excited to see a new sequencing technology,” said Andrew Carroll, Product Lead – Genomics at Google. “We've observed high data quality with our existing methods, and further improvements with re-trained approaches. We've seen especially good performance at lower coverages, which suggests Element may have some read-level accuracy advantages."

Detailed results of the studies with Sentieon and Google will be released March 14, 2022.

About Google

Google’s mission is to organize the world’s information and make it universally accessible and useful. Through products and platforms like Search, Maps, Gmail, Android, Google Play, Chrome, and YouTube, Google plays a meaningful role in the daily lives of billions of people and has become one of the most widely-known companies in the world. Google is a subsidiary of Alphabet Inc. For more information, visit our Google AI Blog.

About Sentieon

Sentieon® develops award winning, extremely accurate and highly-optimized algorithms and software for bioinformatics data processing applications. Sentieon® is a team of professional engineers with deep expertise in algorithm, software, and system optimization acquired through experience developing image processing, computational lithography, large-scale data mining, and bioinformatics applications. Using our accumulated expertise in modeling, optimization, machine learning, and high-performance computing, we strive to enable precision data for precision medicine. Visit our website for more information.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Forges New Partnerships with Industry Leaders

2022-02-23T18:31:00-08:00

Test 1

High-quality library preparation is critical for high-performance next-generation sequencing. Recognized leaders in this field are powerful innovators, combining both a deep understanding of customer needs and the advanced technologies required to serve them.

At Element Biosciences, we are proud to partner with these remarkable companies with whom we share the same vision, to drive greater access to powerful genomic technologies and provide the freedom to discover more!

Links to the individual press releases for each collaboration are listed below in alphabetical order:

To learn more about these partnerships, register for our virtual launch event on March 14, at 9am PT.

We'll be unveiling product specs, data quality, and the price of our new benchtop DNA sequencer, AVITI™ — as well as hearing testimonials from early adopters, presentations from industry leaders, app notes, and more!

So come join us, bring your best questions, and Be In Your Element.

Element Partners with Dovetail Genomics to Validate its Proximity Ligation-Based NGS Library Prep Solutions for Epigenetics on Element’s AVITI™ System

2022-02-23T16:16:00-08:00

Dovetail Genomics and Element Biosciences partner to deliver seamless compatibility between Element's AVITI™ system and Dovetail's library preparation kits.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Dovetail Genomics demonstrating the value and performance of Dovetail’s proximity ligation-based next-generation sequencing (NGS) library prep solutions on Element’s AVITI™ System.

The ability to unlock access to genomic structure enables cutting-edge science in the fields of epigenetics, developmental biology, cancer research, conservation, and evolutionary biology. Advances in chromatin conformation capture technologies that sit at the forefront of this effort. Dovetail Genomics’ best-in-class products and services capture 3D genome architecture alongside primary sequence information using NGS approaches.

“We are pleased to form a partnership with Dovetail Genomics to deliver seamless compatibility between the AVITI™ System and Dovetail’s library preparation kits. Their proximity ligation technology couples well with Element’s improvements in sequencing accuracy, lower optical duplication rate, and consistency of data, across a range of applications,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs at Element Biosciences.

“We are thrilled to partner with Element Biosciences to add Dovetail Genomics’ cutting-edge proximity ligation technology to this new and exciting NGS platform,” said Dovetail CEO Todd Dickinson. “The long-range, unbiased nature of the Dovetail data opens up many new applications not typically accessible with a short-read platform, offering a richer view of the genome from every sequencing run.”

About Dovetail Genomics

Dovetail Genomics is reimagining the life sciences by unlocking access to genomic structure at an unparalleled level. Through Dovetail Genomics' proprietary proximity ligation technologies, the 3D architecture of the genome is captured alongside primary sequence information using standard next-generation sequencing (NGS) approaches. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing and microbiome analysis in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more.
Learn more about Dovetail here, including its technology and service offerings, or follow Dovetail on Twitter @DTGenomics.
Media contact for Dovetail Genomics: Michael Sullivan | dovetail@teamseismic.com | (503) 799-7520

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine.
Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element and Jumpcode Genomics Partner to Validate Jumpcode’s CRISPRclean® Technology on Element’s AVITI™ System for a Broad Set of Genomic Applications

2022-02-23T15:17:00-08:00

Element Biosciences and Jumpcode Genomics partner to improve next-generation DNA sequencing.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a collaboration and co-marketing partnership with Jumpcode Genomics that validates Jumpcode's CRISPRclean® technology on Element’s AVITI™ System. The partnership has already demonstrated the value of pairing the technologies, promising improved data quality and cost savings across various genomic applications.

Jumpcode’s CRISPRclean® technology harnesses the specificity of CRISPR-Cas9 to degrade abundant, uninformative sequences in next-generation sequencing (NGS) libraries. In both single-cell gene expression and infectious disease detection assays, target refinement via CRISPRclean® has a tremendous impact on read depth, coverage, and signal quality.

Element’s AVITI™ system utilizes avidity sequencing to provide a lower error rate and higher data quality.

By combining CRISPERclean® and AVITI™, users can focus on lower-expressing transcripts in single-cell samples, effectively shifting sequencing power in a way that gains deeper coverage and improved signal. The AVITI™ System detected a 50% increase in genes per cell and classified additional cell types in human blood samples treated with CRISPRclean®. For surveillance studies of infectious agents, CRISPRclean® and AVITI™ offer significant benefits in sensitivity, cost, and throughput. Analyzing SARS-CoV-2 infected human samples treated with CRISPRclean® to remove uninformative sequences, the AVITI™ System detected variants and host response at a cost unrivaled by other benchtop sequencers.

“Element’s sequencing technology has demonstrated improved sequencing efficiency and more uniform data quality with Jumpcode libraries. The synergies between our technologies generate more targeted data per run, lowered overall costs per sample, with consistently high data quality,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs at Element Biosciences. “Jumpcode’s capabilities enhance sensitivity and improve resolution for several applications.”

“At Jumpcode, we’re empowering scientists to drive innovation in genomic research and diagnostics,” said Yaron Hakak, CEO of Jumpcode Genomics. “There have been many challenges in realizing the full potential of NGS for basic research, infectious disease, oncology, and consumer genomics &emdash; including unwanted sequences that can mask important genomic information. We’re proud to collaborate with Element Biosciences to help those studying genomics cut through the noise.”

About Jumpcode Genomics

Jumpcode Genomics is changing genomics with technology that allows scientists to break barriers limiting their research. Combining CRISPR-based technology and next-generation sequencing, it’s now possible to search for and find novel signals that were previously undetectable. Our technology removes unwanted sequences, allows researchers to extract greater insights, and broadens the understanding of human biology in fields from research to clinical applications. Discover what Jumpcode Genomics can do here.
Media contact for Jumpcode Genomics: Kelley Falisi | jumpcodegenomics@shiftcomm.com | (215) 622-5554

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with Agilent Technologies to Validate SureSelect™ Target Enrichment Panels on Element’s AVITI™ System

2022-02-22T04:50:00-08:00

Element Biosciences and Agilent Technologies have integrated Element's AVITI System with Agilent's SureSelect target enrichment panels.

Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Agilent Technologies demonstrating the integration of Element’s AVITI System with Agilent Technologies’ industry-leading SureSelect target enrichment panels, providing customers greater access to these genomic tools.

Target enrichment as a pre-sequencing DNA preparation method is invaluable for clinical and industrial applications where accuracy, cost-effectiveness, and throughput are critical. As a leader in hybridization-based target enrichment, Agilent’s SureSelect sequencing panels are highly sensitive and enable detection of single-nucleotide, structural and copy number variants, fusions, insertions, and deletions.

“Element’s sequencing quality, lower duplication rates, and platform flexibility seamlessly integrate with Agilent’s widely used target enrichment technology. Our partnership with Agilent has validated our AVITI system with the SureSelect hybrid-capture target enrichment solutions,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. “This partnership will advance target enrichment and sequencing on the AVITI system to deliver exceptional value and performance to our customers.”

“We are excited to collaborate with Element Biosciences in enabling the next step forward in performance and efficiency for this essential NGS technology,” stated Kevin Meldrum, Vice President and General Manager for Agilent’s Integrated Genomics Division. “Demonstrating the successful combination of the AVITI platform with the SureSelect portfolio will help NGS users leverage our trusted and proven SureSelect solution. Our partnership will accelerate adoption of this powerful genomic analysis tool while minimizing re-design and improving lab optimization efforts.”

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with New England Biolabs® to launch new NEBNext® Ultra™ II Kits specifically designed for the Element AVITI™ System

2022-02-22T04:45:00-08:00

This partnership integrates the performance, cost, and flexibility of the Element AVITI System with New England Biolabs' powerful NEBNext Ultra II library prep technology to provide a unique end-to-end solution for Element sequencing customers and further expand the well-established NEBNext Ultra II technology.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with New England Biolabs (NEB®) to commercially develop and launch products to enable compatibility of the NEBNext Ultra II portfolio with the Element AVITI System.

High-quality library preparation is critical for high-performance sequencing. NEB has a long and successful track record of developing enzymes and workflow solutions for NGS library preparation. A recognized leader in the field, NEB has a deep understanding of customer needs for NGS library preparation, the challenges of diverse sample inputs, and the demands of consistently producing some of the highest quality products in the industry.

“We are excited about the partnership with NEB and very proud of the new NEBNext Ultra II workflows developed specifically for Element Bioscience customers. This partnership is the culmination of our shared vision to make powerful genomics solutions more broadly accessible to all scientists,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. “Leveraging the combination of NEB’s exceptional molecular biology capabilities with Element’s cost-effective, flexible, and high-performance sequencing will drive our shared vision forward.”

“In partnership with Element Biosciences, we are excited to apply our NEBNext library prep technologies and expertise to this innovative new sequencing platform,” said Fiona Stewart, Ph.D., Associate Director, NGS Portfolio Management. “We look forward to enabling streamlined high-performance library prep workflows for Element sequencing.”

About New England Biolabs

Established in the mid-1970s, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next-generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, USA, and has extensive worldwide distribution through a network of exclusive distributors, agents, and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore, and the UK. For more information about New England Biolabs visit www.neb.com.

NEW ENGLAND BIOLABS®, NEB® and NEBNEXT® are registered trademarks of New England Biolabs, Inc.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Element’s AVITI™ System

2022-02-22T04:40:00-08:00

Element Biosciences and QIAGEN partner to validate QIAGEN's NGS library prep on Element's AVITI System.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System. This partnership demonstrates the compatibility of the Element AVITI System’s performance, cost, and flexibility with a selection of QIAGEN’s most popular QIAseq target enrichment panels.

“QIAGEN’s breadth and scope of products supporting NGS workflows are unique. Their product portfolio and bioinformatics solutions create many potential synergies between our respective capabilities,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. “Element’s sequencing improvements and platform efficiencies integrate well with QIAGEN’s portfolio, and toward our shared goal of flexible, cost-effective and high-performance targeted solutions for our customers.”

“We are delighted to be part of Element’s partner network to develop and validate QIAGEN’s QIAseq NGS applications on Element’s NGS platforms,” said Dr. Thomas Schweins, Senior Vice President and Head of Life Sciences, QIAGEN. “This is part of QIAGEN’s strong commitment to be a key enabler of advanced genomics applications with emerging and strategic NGS platform providers. We believe that the partnership with Element is of great value to customers and will provide a continually expanding choice of technologies and menu of applications to advance their genomics research.”

The QIAseq portfolio has an established track record of enabling customers across many life science research segments with the ability to detect and characterize changes in the genome, transcriptome, methylome, and microbiome. As part of an integrated technology ecosystem, it includes curated databases, advanced primer designs, proprietary chemistries, cloud-based bioinformatics, and customizable content to address significant customer needs for discovering previously undetected genetic variants and changes in gene expression.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company (www.QIAGEN.com), is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies), and Academia (life sciences research). As of December 31, 2021, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Learn more about QIAGEN’s QIAseq.
Media contact for QIAGEN: Thomas Theuringer | pr@QIAGEN.com | +49 2103 29 11826

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element's New AVITI™ System Shows Seamless Compatibility and High Performance with KAPA Library Preparation Kits in Multiple NGS Applications

2022-02-22T04:35:00-08:00

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a key technical milestone using the Roche KAPA HyperPlus and KAPA EvoPlus library preparation and target enrichment kits in microbial whole genome, human whole genome, and human whole-exome sequencing applications.

High-quality library preparation is critical for high-performance sequencing. Roche, through its KAPA brand, offers advanced solutions for NGS library preparation, consistently producing some of the highest quality products in the industry.

"The ability to share and integrate data between studies is foundational in genomics. Validating such data integration has been limited, however. We are pleased to announce a technical milestone: we have confirmed the AVITI System's compatibility with KAPA technology, a large, important application segment of Next Generation Sequencing," said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. "Generating data that is equal to or better than leading platforms and demonstrating this data can be integrated between leading technology platforms benefits customers with flexibility and cost-effectiveness novel to the field."

"Demonstrating compatibility of our KAPA chemistry with Element's sequencing platform offers our customers more flexibility across applications and sequencing platforms to address the growing need for high performing NGS solutions," said Cindy Perettie, Head of Molecular Labs, Roche Diagnostics Solutions.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Partners with Watchmaker Genomics to Validate Watchmaker Library Preparation Kits on Element’s AVITI™ System

2022-02-22T04:30:00-08:00

Element Biosciences & Watchmaker Genomics are partnering to validate Watchmaker library preparation kits on Element's AVITI System

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Watchmaker Genomics demonstrating the value and performance of Watchmaker’s DNA and RNA Library Prep Kits on Element’s AVITI System.

High-quality libraries that accurately represent starting samples — especially from a diverse range of sources — are essential for generating meaningful biological insights from sequence data. Watchmaker’s expertise in purpose-engineering enzymes and NGS workflow solutions make them well-suited to address increasingly stringent sample preparation needs and facilitates the AVITI platform’s continued improvements in sequencing platform accuracy and flexibility.

“Watchmaker’s robust results demonstrate the seamless compatibility of the AVITI System with their library preparation kits,” said Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences. “AVITI’s sequencing quality, flexibility, and performance provide unique opportunities to leverage Watchmaker’s capabilities in engineering enzymes and workflows.”

“The rapid evolution of NGS applications over the last decade underscores the need for tailored sequencing solutions. Element Biosciences’ benchtop sequencer — with its flexible sequencing configurations and high data quality — increases access and choice in both research and clinical settings,” said Kerri Stellato, Vice President of Strategic Marketing at Watchmaker Genomics.

About Watchmaker Genomics

Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines deep domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications.

Watchmaker’s product portfolio includes enzymes and kits for next-generation sequencing library preparation, synthetic biology, and molecular diagnostics. Based in Boulder, Colorado, the Watchmaker team brings decades of collective experience building successful life science companies, commercializing novel technologies, and advancing clinical genomics applications. Watchmaker partners directly with innovative life science companies, commercial sequencing providers, and pioneering research labs. For more information, visit www.watchmakergenomics.com.
Media contact for Watchmaker Genomics: Kerri Stellato | kerri.stellato@watchmakergenomics.com | (617) 620-7667

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.
Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

Element Strengthens Leadership Team to Advance Novel Applications Development and Scientific Affairs

2022-02-15T05:00:00-08:00

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced the appointment of Shawn Levy, Ph.D., as Senior Vice President of Applications and Scientific Affairs. A world-renowned pioneer in genomics research, Dr. Levy brings more than 20 years of in-depth knowledge to support Element's growth and strategic plans for its first sequencing platform, AVITI^™, and future platforms beyond sequencing.

“Dr. Levy is one of the most respected and influential researchers and innovators in genomics, and we are thrilled to welcome him to the team,” said Molly He, Ph.D., CEO, and co-founder of Element. “In his role as Element's Senior Vice President of Applications and Scientific Affairs, Dr. Levy will be responsible for a multidisciplinary team focused on developing applications and methodologies to leverage the unique capabilities of the AVITI sequencer. Dr. Levy will also provide invaluable leadership to drive external partnerships and collaborations with academic, industry, and commercial entities to advance Element's mission to accelerate our collective impact on humanity.”

Prior to joining Element, Dr. Levy served as Chief Scientific Officer at Discovery Life Sciences where he was responsible for research and development programs and scientific strategy. Dr. Levy remains a faculty investigator at the HudsonAlpha Institute for Biotechnology and adjunct faculty at the University of Alabama-Birmingham. He holds a Ph.D. in Biochemistry from Emory University School of Medicine.

“I have been fortunate to work with an amazing diversity of colleagues and collaborators over the last 21 years and I am exceptionally proud of our accomplishments and efforts. Element's unique vision to break scientific boundaries and their commitment to innovation and creativity are truly enabling for researchers,” said Dr. Levy. “I am excited to join the Element team and contribute to the mission and culture of the company while building on the relationships I've been fortunate to establish in the field of genomics and beyond.”

Element Biosciences Closes Acquisition of Loop Genomics

2022-02-07T10:53:00-08:00

Element Biosciences has closed its acquisition of Loop Genomics, a long-read solutions company that enables short-read sequencers to obtain long-range information.

Element Biosciences will offer both short-read and long-read sequencing on a common platform.

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced that the company has closed its acquisition of Loop Genomics, a long-read solutions company that enables short-read sequencers to obtain long-range information. Loop Genomics' Chief Executive Officer and Founder, Tuval Ben-Yehezkel, PhD, will join Element Biosciences' leadership team as Senior Director, Applications.

By combining Element's highly accurate and cost-effective short-read platform with Loop's easy and scalable long-read solutions, customers will be able to access both short- and long-read applications on the same platform with unprecedented performance, cost, and flexibility.

"Loop Genomics has successfully commercialized innovative products that bring long-read resolution to short-read platforms in a wide variety of genetic analysis applications. We are thrilled to have the Loop Genomics team join us on our journey to open the world of biology to new possibilities," said Molly He, PhD, co-founder, and chief executive officer of Element Biosciences.

"Element's new sequencer, now armed with long-read capabilities, is positioned to disrupt the genomics space. We are excited to join forces with the team at Element and are looking forward to providing our customers with superior short- and long-read sequencing products," said Tuval Ben-Yehezkel.

Element's inaugural virtual event on March 14, 2022, will provide more details on the Loop Genomics technology and its integration with the Element platform.

Financial terms of the transaction were not disclosed.

About Element Biosciences

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine.

Learn More About Element Biosciences

About Loop Genomics

Loop Genomics is a synthetic long-read sequencing company developing and commercializing products in a wide variety of genetic analysis applications, including among others, genome, transcriptome, microbiome, and immune repertoire sequencing. Its technology includes fundamental innovations in DNA sequencing chemistry and software, which transform short read sequencers into highly accurate long read sequencers. These, in turn, provide previously inaccessible genetic information that can be used in scientific discovery as well as applied genomics data in domains as diverse as human health, animal health, agriculture, and the environment.

Learn More About Loop Genomics

Element Biosciences Bolsters Leadership Team to Advance Development and Commercialization of DNA Sequencing Platform

2021-07-20T05:50:00-07:00

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced the appointments of Brian Stolz as Chief People Officer, Diana King as Vice President of Customer Support, and Jordan Neysmith as Vice President of Engineering. The new leadership appointments follow the recent close of $276 million in Series C financing and support the company’s growth and strategic plans for the development and commercialization of a disruptive DNA sequencing platform.

“We’re fortunate to have attracted the high caliber of expertise that Brian, Diana, and Jordan bring to the Element team to help us transform the genomics industry,” said Molly He, Ph.D., CEO and co-founder of Element. “As proven leaders in the health and life science industry, they each bring an impressive track record in their respective fields, having built and scaled best-in-class HR, customer support, and engineering teams. We are focused on growing a team that is both deeply passionate about reimagining DNA sequencing and believes in our mission to dramatically expand access to high quality, low cost, easy-to-use genomics tools.”

In his role as Element’s Chief People Officer, Brian Stolz will be responsible for human resources strategy, talent acquisition, leadership development, diversity and inclusion, organizational design and cultural development, employee education and development, compensation and benefits, and HR operations and technology. Prior to joining Element, he served as Chief Operating Officer at BridgeBio where he was responsible for scaling an organization with over 20 R&D programs focused on developing treatments for rare diseases, as well as overseeing human resources, legal, facilities, philanthropy, diversity, equity & inclusion and board management. He also served as Chief People Officer for Activision Blizzard, working directly with the CEO to establish the right structure, systems, processes and talent to execute the company’s growth plans. Previously, he held executive roles at Bausch Health Companies Inc. and McKinsey & Company. He holds a BS in Finance from Georgetown University and an MBA from Harvard University.

Diana King is an accomplished service and support executive. She joins Element from MULTI, INC, a global provider of advanced medical imaging solutions, where she served as Chief Business Development Officer. Previously, she held service and support leadership roles at Agfa Radiology Solutions, Prime Healthcare, and GE Healthcare. Diana holds a BS in Computer Engineering and an MBA from Texas A&M University.

Jordan Neysmith is a dynamic and accomplished leader in research, development and product management at innovative technology companies. He joins Element from Bruker Nano Surfaces, where he served as Senior Director of Development and Engineering, having led a global product development organization that included systems, hardware, software and test engineering. Previously, he held engineering leadership positions at Carl Zeiss Meditec, Inc., Earlens Corporation, and Second Sight Medical Products, Inc. He holds a BS in Mechanical Engineering from Yale University and a MS in Mechanical Engineering from the Georgia Institute of Technology.

“The team that Element is assembling to realize its mission to democratize access to genomics is absolutely incredible and includes the foremost experts in their fields. The team has some of the most brilliant scientific minds in the genomics industry -- all of whom are empowered to challenge the status quo and create a new bellwether for the industry,” said Brian Stolz, Chief People Officer of Element. “As we advance toward commercialization, we will continue to recruit top scientific and business talent. I look forward to solidifying Element’s position as an ‘employer of choice’ for those passionate about enabling and inspiring cutting-edge science in genomics and to working with Molly and the management team to build the talent, leadership and culture to accelerate the company’s growth plans.”

Element Biosciences Closes $276 Million Series C Financing to Democratize Access to Genomics

2021-06-29T06:00:00-07:00

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced the close of a $276 million Series C financing. New investors Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Counterpoint Global (Morgan Stanley), and T. Rowe Price joined existing investors Fidelity Management & Research Company, Foresite Capital, JS Capital Management LLC, RA Capital Management, and Venrock. With this latest investment, Element Biosciences has raised approximately $400 million.

“Element will provide researchers with innovative technology choices and more flexible tools for scientific exploration,” said Molly He, Ph.D., co-founder and chief executive officer of Element Biosciences. “We are working to realize our vision of dramatically expanding access to high quality, low cost, easy-to-use genomics tools.”

Genome sequencing has become an increasingly powerful tool to understand biology and improve human life, from decoding the basis for infectious diseases like COVID-19 to the genetic profile of individual cancers, inherited diseases, and beyond. Proceeds from the Series C financing will be used to scale the commercial organization in anticipation of, as well as fund, the launch of the company’s next-generation sequencing solution.

“Element has developed a differentiated, modular, platform-based approach that reinvents all aspects of a DNA sequencing solution,” said John Stuelpnagel, DVM, chairman of the Element Biosciences Board of Directors. “The company has the vision and executional roadmap needed to support current and emerging opportunities in the genomics research market.”

“The ability to partner with Fidelity, Janus Henderson, Counterpoint Global (Morgan Stanley) and T. Rowe Price in building our company is a testament to Element's technology, people and collective teamwork,” said Bryan Roberts Ph.D., partner at Venrock and a member of the Element Biosciences Board of Directors. “We look forward to a long relationship with them, and all of Element’s investors.”

Element Biosciences Appoints Chief Commercial Officer, General Counsel, and VP of Operations

2021-04-20T09:44:00-07:00

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced the appointments of Jeff Journey as Chief Commercial Officer, David Melaugh as General Counsel, and Jeff Labbadia as VP of Operations.

“We are thrilled to welcome Jeff, David, and Jeff to the Element team,” said Molly He, Ph.D., CEO and co-founder of Element. “They are strategic leaders in the technology and life science industry, each with an impressive track record in building and scaling best-in-class commercial, legal, and operations teams, respectively. As we gear up for production and commercialization of our first product, the depth and breadth of their experience will help Element deliver on our promise of empowering the scientific community with unprecedented freedom to study biology.”

Jeff Journey brings more than 30 years of leadership experience in a range of industries to the position. Most recently, Jeff was VP/General Manager at Thermo Fisher Scientific where he oversaw the $1B+ Sample Preparation business unit with full P&L, strategy, development, and commercialization responsibilities. Prior to that, he held various leadership roles in marketing, sales, service and support, and strategy at Thermo Fisher Scientific, Johnson & Johnson and GE. Jeff is a veteran of the U.S. Air Force and served for seven years as a commissioned officer.

David Melaugh joins Element from Apple, where he was the Senior Director in charge of Apple’s worldwide intellectual property litigation team. During his 11 years at Apple, David was responsible for strategic management of Apple's global IP litigation docket during the thick of the “smartphone wars” that followed Apple’s iPhone launch – regarded as some of the most complex and wide-ranging civil litigation ever. He is the recipient of numerous national legal awards, including Managing Intellectual Property’s In-House Team of the Year. Before Apple, David was a partner at Morrison & Foerster, where he represented a wide variety of high technology companies.

Jeff Labbadia joins Element after 22 years at Becton Dickinson, where he consistently enabled commercial success through various global operations leadership roles. As a deeply analytical operations strategist, Jeff specializes in value capture, enterprise resource management, supply chain scale-up and optimization, and has tremendous experience with both life science products and regulated medical devices in high growth and large-scale environments.

“Element is entering a phase of rapid growth and expansion, with many exciting opportunities around the corner,” said Jeff Journey, Chief Commercial Officer of Element. “I’m tremendously honored to join this incredibly innovative and collaborative team at Element. We are excited to bring transformative solutions to the market that will empower more scientists and accelerate genomic discoveries.”

Element Raises $30M in Additional Series B Financing to Accelerate Development of a New Sequencing Platform

2020-06-26T08:25:00-07:00

Element Biosciences raised an additional $30M in Series B financing, with participation from new investors RA Capital Management and Alexandria Venture Investments. Proceeds from the financing will be used to accelerate the development of a new DNA sequencing platform. To date, the company has raised a total of more than $130M.

Element Biosciences Raises $80M in Series B Financing to Accelerate Development of a New DNA Sequencing Platform

2020-01-09T17:17:00-08:00

Element Biosciences today announced the close of a Series B financing round of $80.3 million, with participation from new investors Fidelity Management & Research Company and JS Capital LLC, as well as existing investors Foresite Capital and Venrock. To date, the company has raised a total of more than $100 million. Proceeds from the financing will be used to accelerate the development of high-quality, low-cost, and easy-to-use genomic sequencing solutions.

Genetic sequencing has become an increasingly powerful tool to understand biology and improve human life. While the market is rapidly growing, it is still challenging for individual labs to access such reliable tools without a significant amount of capital and operating knowledge. The genomics industry needs more competitive players to accelerate research and discovery.

“Element’s vision is to create disruption in each of the basic elements that comprise a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. With a combination of Element’s proprietary technologies and the latest developments in these respective areas, we have developed a flexible, modular, and high-performing sequencing platform,” said Molly He, PhD, CEO and co-founder of Element.

With the completion of this financing round, Element will focus on critical product development activities this year, including integration of the company’s innovations to date. To support its ambitious growth trajectory, Element has recently moved its headquarters in San Diego into a new 30,000-square-foot facility in University Towne Center. Element will continue to expand its team in both San Diego and the San Francisco Bay Area, and will be joined by suppliers and partners sharing the same vision.

“Rebuilding a sequencing platform with the modularity for growth beyond a tool company is a remarkable undertaking. It takes fundamental changes of not only the technical system, but also the mentality of a company. The company seeks to deliver unprecedented freedom to study biology in an open and collaborative manner to advance genomics research as a community,” said John Stuelpnagel, DVM, Chairman of Element since its inception in 2017. “Element has assembled a special group, wired with the courage and creativity to pull off this undertaking.”

Element Biosciences Moves to Alexandria GradLabs in Anticipation of Growth and Expansion

2019-12-16T08:22:00-08:00

Element Biosciences, Inc. just moved its headquarters into a new 30,000-square-foot life-science space on the Alexandria GradLabs campus, bordering the University of California, San Diego. The well-equipped site will provide a highly flexible and amenity-rich environment to nurture and accelerate critical product development activities as well as support its ambitious growth trajectory. Element will continue to expand the team in both San Diego and the San Francisco Bay Area and will be joined by suppliers and partners sharing the same vision.

Element Biosciences, Inc.
9880 Campus Point
San Diego, CA 92121
info@elembio.com
(619) 353-0300

Element Biosciences Secures $15 Million Series A Financing Led by Foresite Capital and Venrock

2019-06-18T08:18:00-07:00

Element Biosciences, Inc., a company focused on the development of genetic analysis tools secures $15 million in Series A funding led by Foresite Capital and Venrock. Proceeds from the financing will support the development of disruptive technologies designed to significantly improve quality and reduce the cost of genomic applications.

“The capital raised will fuel the company's R&D to implement innovative changes across each element, from reagents to instrument to data analysis. We are on an aggressive path to introduce a high quality, flexible platform to make genetic analysis more accessible and adaptable to a broad customer base,” said Molly He, co-founder and CEO of Element.

Element has assembled a preeminent leadership team with proven experience developing genetic tools. The Board of Directors comprises executives with broad experiences for each element of genetic analysis.

“During the last decade, we have seen genetic analysis become a mainstay of basic and clinical research primarily through platforms that resemble mainframe computers. As genetic analysis applications continue to explode, we expect the platforms to continue to evolve. We believe the Element team is well positioned to create new genetic analysis tools to meet maturing market needs,” says Jim Tananbaum, CEO and managing director of Foresite Capital.

“Materially improved pricing and performance benchmarks for genetic analysis, in an easy to use package, would dramatically increase use cases and thereby propel our understanding of biology to new levels. This is Element’s mission,” said Bryan Roberts, partner at Venrock.